Amedeo Smart

Free Medical Literature Service

 

Amedeo

Neoplasms of the CNS
  Free Subscription

Articles published in
Neuro Oncol
    April 2024
  1. PACKER RJ
    Very long-term outcomes of pediatric patients treated for optic pathway gliomas: A longitudinal cohort study.
    Neuro Oncol. 2024 Apr 17:noae079. doi: 10.1093.
    >> Share

  2. ANASTASAKI C, Chatterjee J, Koleske JP, Gao Y, et al
    NF1 mutation-driven neuronal hyperexcitability sets a threshold for tumorigenesis and therapeutic targeting of murine optic glioma.
    Neuro Oncol. 2024 Apr 12:noae054. doi: 10.1093.
    >> Share

  3. TOHIDINEZHAD F, Zegers CML, Vaassen F, Dijkstra J, et al
    Predicting the risk of neurocognitive decline after brain irradiation in adult patients with a primary brain tumor.
    Neuro Oncol. 2024 Apr 10:noae035. doi: 10.1093.
    >> Share

  4. GEURTS M, Preusser M
    Locoregional delivery of CAR-T cells - breaking the spell in glioblastoma?
    Neuro Oncol. 2024 Apr 9:noae063. doi: 10.1093.
    >> Share

  5. ARRILLAGA-ROMANY I, Miller JJ
    Demonstrated efficacy and mechanisms of sensitivity of ONC201: H3K27M-mutant diffuse midline glioma in the spotlight.
    Neuro Oncol. 2024 Apr 8:noae051. doi: 10.1093.
    >> Share

  6. OBRECHT-STURM D, Schomig L, Mynarek M, Bison B, et al
    Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent MRI lesions after first-line treatment.
    Neuro Oncol. 2024 Apr 5:noae071. doi: 10.1093.
    >> Share

  7. CIOFFI G, Waite KA, Price M, Neff C, et al
    The impact of COVID-19 on 2020 monthly incidence trends of primary brain and other CNS tumors.
    Neuro Oncol. 2024;26:764-774.
    >> Share

  8. APPIN CL, Hong C, Suwala AK, Hilz S, et al
    Whole tumor analysis reveals early origin of the TERT promoter mutation and intercellular heterogeneity in TERT expression.
    Neuro Oncol. 2024;26:640-652.
    >> Share

  9. DUMOT C, Mantziaris G, Dayawansa S, Peker S, et al
    Stereotactic radiosurgery for nonfunctioning pituitary tumor: A multicenter study of new pituitary hormone deficiency.
    Neuro Oncol. 2024;26:715-723.
    >> Share

  10. BUDHU JA, Chukwueke UN, Jackson S, Lee EQ, et al
    Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effort.
    Neuro Oncol. 2024;26:596-608.
    >> Share

  11. BROMBERG JEC, Issa S, van der Holt B, van der Meulen M, et al
    Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.
    Neuro Oncol. 2024;26:724-734.
    >> Share

  12. RICKLEFS FL, Wollmann K, Salviano-Silva A, Drexler R, et al
    Circulating extracellular vesicles as biomarker for diagnosis, prognosis and monitoring in glioblastoma patients.
    Neuro Oncol. 2024 Apr 3:noae068. doi: 10.1093.
    >> Share

    March 2024
  13. XIE H, Jiang Y, Xiang Y, Wu B, et al
    Super-enhancer-driven LIF promotes the mesenchymal transition in glioblastoma by activating ITGB2 signaling feedback in microglia.
    Neuro Oncol. 2024 Mar 30:noae065. doi: 10.1093.
    >> Share

  14. DE LA NAVA D, Ausejo-Mauleon I, Laspidea V, Gonzalez-Huarriz M, et al
    The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models.
    Neuro Oncol. 2024 Mar 30:noae066. doi: 10.1093.
    >> Share

  15. IVANIDZE J, Chang SJ, Haghdel A, Kim JT, et al
    [Ga68] DOTATATE PET/MRI-Guided Radiosurgical Treatment Planning and Response Assessment in Meningiomas.
    Neuro Oncol. 2024 Mar 30:noae067. doi: 10.1093.
    >> Share

  16. MCCORD M, Jamshidi P
    Targeting the cell cycle to enhance chemotherapy efficacy in glioblastoma.
    Neuro Oncol. 2024 Mar 22:noae062. doi: 10.1093.
    >> Share

  17. RYBA A, Ozdemir Z, Nissimov N, Honikl L, et al
    Insights from a Multicenter Study on Adult H3 K27M-Mutated Glioma: Surgical Resection's Limited Influence on Overall Survival, ATRX as Molecular Prognosticator.
    Neuro Oncol. 2024 Mar 20:noae061. doi: 10.1093.
    >> Share

  18. ALVAREZ-VAZQUEZ A, San-Segundo L, Cervero-Garcia P, Flores-Hernandez R, et al
    EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models.
    Neuro Oncol. 2024 Mar 20:noae060. doi: 10.1093.
    >> Share


  19. Corrigendum to: Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.
    Neuro Oncol. 2024 Mar 20:noae055. doi: 10.1093.
    >> Share

  20. ROTH P, Gorlia T, Reijneveld JC, de Vos F, et al
    Marizomib for patients with newly diagnosed glioblastoma: a randomized phase 3 trial.
    Neuro Oncol. 2024 Mar 19:noae053. doi: 10.1093.
    >> Share

  21. LECHPAMMER M
    Can confocal laser endomicroscopy replace frozen section in diagnosis of brain tumors? A definite maybe.
    Neuro Oncol. 2024 Mar 15:noae042. doi: 10.1093.
    >> Share

  22. LAWLER S
    Identification of transcriptomic signatures associated with glioblastoma recurrence.
    Neuro Oncol. 2024 Mar 12:noae044. doi: 10.1093.
    >> Share

  23. STEVERS NO, Costello JF
    Telomeres in glioma: Maintenance mechanisms to therapeutic potential.
    Neuro Oncol. 2024 Mar 11:noae052. doi: 10.1093.
    >> Share

  24. GALLDIKS N, Kaufmann TJ, Vollmuth P, Lohmann P, et al
    Challenges, Limitations and Pitfalls of PET and Advanced MRI in Patients with Brain Tumors - A Report of the PET/RANO Group.
    Neuro Oncol. 2024 Mar 11:noae049. doi: 10.1093.
    >> Share

  25. MOREIRA DC, Qaddoumi I, Spiller S, Bouldin TW, et al
    Comprehensive analysis of MYB/MYBL1-altered pediatric-type diffuse low-grade glioma.
    Neuro Oncol. 2024 Mar 11:noae048. doi: 10.1093.
    >> Share

  26. MORIN A, Allodji R, Kariyawasam D, Touraine P, et al
    Very long-term outcomes of pediatric patients treated for optic pathway gliomas: A longitudinal cohort study.
    Neuro Oncol. 2024 Mar 11:noae045. doi: 10.1093.
    >> Share

  27. NAGPAL S, Milano MT, Chiang VL, Soltys SG, et al
    Executive Summary of the American Radium Society Appropriate Use Criteria for Brain Metastases in EGFR-mutated and ALK-fusion Non-Small Cell Lung Cancer.
    Neuro Oncol. 2024 Mar 9:noae041. doi: 10.1093.
    >> Share

  28. HUANG H, Shah H, Hao J, Lin J, et al
    LncRNA LUCAT1 Promotes Glioblastoma Progression by Enhancing HIF1alpha Activity.
    Neuro Oncol. 2024 Mar 8:noae036. doi: 10.1093.
    >> Share

  29. TABOURET E, Furtner J, Graillon T, Silvani A, et al
    3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas.
    Neuro Oncol. 2024 Mar 7:noae037. doi: 10.1093.
    >> Share

  30. ARRILLAGA-ROMANY I, Lassman A, McGovern SL, Mueller S, et al
    ACTION: A randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.
    Neuro Oncol. 2024 Mar 6:noae031. doi: 10.1093.
    >> Share

  31. LEE MD, Jain R
    Harnessing Generative AI for Glioma Diagnosis: A Step Forward in Neuro-Oncologic Imaging.
    Neuro Oncol. 2024 Mar 5:noae043. doi: 10.1093.
    >> Share

  32. SHIXUE Y, Qi Z, Dongyuan S, Xiaoteng C, et al
    HIF1alpha/ATF3 partake PGK1 K191/K192 succinylation by modulating P4HA1/succinate signaling in glioblastoma.
    Neuro Oncol. 2024 Mar 5:noae040. doi: 10.1093.
    >> Share

  33. TSENG CL, Zeng KL, Mellon EA, Soltys SG, et al
    Evolving concepts in margin strategies and adaptive radiotherapy for glioblastoma: A new future is on the horizon.
    Neuro Oncol. 2024;26.
    >> Share

  34. PALMER JD, Perlow HK, Lehrer EJ, Wardak Z, et al
    Novel radiotherapeutic strategies in the management of brain metastases: Challenging the dogma.
    Neuro Oncol. 2024;26.
    >> Share

  35. KOTECHA R, La Rosa A, Mehta MP
    How proton therapy fits into the management of adult intracranial tumors.
    Neuro Oncol. 2024;26.
    >> Share

  36. BREEN WG, Aryal MP, Cao Y, Kim MM, et al
    Integrating multi-modal imaging in radiation treatments for glioblastoma.
    Neuro Oncol. 2024;26.
    >> Share

  37. MAYO ZS, Billena C, Suh JH, Lo SS, et al
    The dilemma of radiation necrosis from diagnosis to treatment in the management of brain metastases.
    Neuro Oncol. 2024;26.
    >> Share

  38. SAHGAL A, Chang S
    Pushing the boundaries of radiation technology for the management of central nervous system tumors.
    Neuro Oncol. 2024;26.
    >> Share

  39. COY S, Lee JS, Chan SJ, Woo T, et al
    Systematic characterization of antibody-drug conjugate targets in central nervous system tumors.
    Neuro Oncol. 2024;26:458-472.
    >> Share

    February 2024
  40. KIDWELL RL, Aghi MK
    Lymphatic endothelial-like cells in the glioblastoma tumor niche drive metabolic alterations that promote stem cell proliferation and survival.
    Neuro Oncol. 2024 Feb 28:noae020. doi: 10.1093.
    >> Share

  41. KE C, Huang B, Xiang J, Liang J, et al
    Secreted Clusterin Inhibits Tumorigenesis by Modulating Tumor Cell and Macrophage in Human Meningioma.
    Neuro Oncol. 2024 Feb 28:noae034. doi: 10.1093.
    >> Share

  42. HILLER-VALLINA S, Mondejar-Ruescas L, Caamano-Moreno M, Comitre-Mariano B, et al
    Sexual-biased necroinflammation is revealed as a predictor of bevacizumab benefit in Glioblastoma.
    Neuro Oncol. 2024 Feb 27:noae033. doi: 10.1093.
    >> Share

  43. ODIA Y, Koschmann C, Vitanza NA, de Blank P, et al
    Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3K27M-mutant glioma.
    Neuro Oncol. 2024 Feb 24:noae001. doi: 10.1093.
    >> Share


  44. Corrigendum to: Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial
    Neuro Oncol. 2024 Feb 23:noae030. doi: 10.1093.
    >> Share

  45. SLOAN AR, Silver DJ, Kint S, Gallo M, et al
    Cancer stem cell hypothesis 2.0 in glioblastoma: Where are we now and where are we going?
    Neuro Oncol. 2024 Feb 23:noae011. doi: 10.1093.
    >> Share

  46. ODIA Y, Hall MD, Cloughesy TF, Wen PY, et al
    Selective DRD2 Antagonist and ClpP Agonist ONC201 in a Recurrent Non-midline H3 K27M-mutant Glioma Cohort.
    Neuro Oncol. 2024 Feb 22:noae021. doi: 10.1093.
    >> Share


  47. Corrigendum to: Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial
    Neuro Oncol. 2024 Feb 16:noae024. doi: 10.1093.
    >> Share

  48. CHENG HS, Chong YK, Lim EKY, Lee XY, et al
    Dual p38MAPK and MEK inhibition disrupts adaptive chemoresistance in mesenchymal glioblastoma to temozolomide.
    Neuro Oncol. 2024 Feb 16:noae028. doi: 10.1093.
    >> Share

  49. SILVESTRI VL, Tran AD, Chung M, Chung N, et al
    Distinct uptake and elimination profiles for trastuzumab, human IgG and biocytin-TMR in experimental HER2+ brain metastases of breast cancer.
    Neuro Oncol. 2024 Feb 13:noae025. doi: 10.1093.
    >> Share

  50. MOREIRA DC, Bouffet E, Qaddoumi I
    The greatest challenge for pediatric low-grade glioma.
    Neuro Oncol. 2024 Feb 10:noae004. doi: 10.1093.
    >> Share

  51. PRINCE EW, Apps JR, Jeang J, Chee K, et al
    Unraveling the Complexity of the Senescence-Associated Secretory Phenotype in Adamantinomatous Craniopharyngioma Using Multi-Modal Machine Learning Analysis.
    Neuro Oncol. 2024 Feb 9:noae015. doi: 10.1093.
    >> Share


  52. Expression of Concern: microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis.
    Neuro Oncol. 2024 Feb 9:noae026. doi: 10.1093.
    >> Share

  53. LAUER EM, Riegler E, Mutter JA, Alig SK, et al
    Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomas.
    Neuro Oncol. 2024;26:374-386.
    >> Share

    January 2024
  54. NELLAN A, Jackson S
    Targeted therapy done right: direct SHH Inhibition for SHH medulloblastoma.
    Neuro Oncol. 2024 Jan 30:noae018. doi: 10.1093.
    >> Share

  55. GHOSH S, Rothlin CV
    TREM2 function in glioblastoma immune microenvironment: can we distinguish reality from illusion?
    Neuro Oncol. 2024 Jan 30:noae019. doi: 10.1093.
    >> Share

  56. CHELLIAH A, Wood DA, Canas LS, Shuaib H, et al
    Glioblastoma and Radiotherapy: a multi-center AI study for Survival Predictions from MRI (GRASP study).
    Neuro Oncol. 2024 Jan 29:noae017. doi: 10.1093.
    >> Share

  57. WAITKUS MS, Erman EN, Reitman ZJ, Ashley DM, et al
    Mechanisms of telomere maintenance and associated therapeutic vulnerabilities in malignant gliomas.
    Neuro Oncol. 2024 Jan 29:noae016. doi: 10.1093.
    >> Share

  58. WANG S, Qi Y, Zhao R, Pan Z, et al
    Copy number gain of FAM131B-AS2 promotes the progression of glioblastoma by mitigating replication stress.
    Neuro Oncol. 2024 Jan 29:noae014. doi: 10.1093.
    >> Share

  59. MACK SC, Bertrand KC
    Understanding the Mechanisms of Diffuse Midline Glioma Cell Migration Towards Therapeutic Targeting.
    Neuro Oncol. 2024 Jan 27:noad263. doi: 10.1093.
    >> Share

  60. DANKNER M, Maritan SM, Priego N, Kruck G, et al
    Invasive growth of brain metastases is linked to CHI3L1 release from pSTAT3-positive astrocytes.
    Neuro Oncol. 2024 Jan 25:noae013. doi: 10.1093.
    >> Share

  61. RANDALL J, Sachdev S
    A valuable glioblastoma prognostic maker driven by radiosensitivity.
    Neuro Oncol. 2024 Jan 23:noad266. doi: 10.1093.
    >> Share

  62. MOON HH, Jeong J, Park JE, Kim N, et al
    Generative AI in glioma: ensuring diversity in training image phenotypes to improve diagnostic performance for IDH mutation prediction.
    Neuro Oncol. 2024 Jan 22:noae012. doi: 10.1093.
    >> Share

  63. SUN Y, Mu G, Xue Z, Wang S, et al
    Polyunsaturated fatty acid-binding protein FABP7, an attractive metabolic target for inhibition of glioblastoma stem cells.
    Neuro Oncol. 2024 Jan 19:noad238. doi: 10.1093.
    >> Share

  64. LIU RZ, Choi WS, Godbout R
    Nuclear translocation matters: Role of FABP7 in driving glioblastoma stemness and invasion: Reply to Mu et al.
    Neuro Oncol. 2024 Jan 19:noad239. doi: 10.1093.
    >> Share

  65. ZIEGLER DS, Lehmann R, Eisenstat DD
    A paradigm shift in how we treat pediatric low grade glioma - targeting the molecular drivers.
    Neuro Oncol. 2024 Jan 19:noae008. doi: 10.1093.
    >> Share

  66. PESHOFF MM, Gupta P, Oberai S, Trivedi R, et al
    Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma.
    Neuro Oncol. 2024 Jan 18:noad257. doi: 10.1093.
    >> Share

  67. FLIES CM, Friedrich M, Lohmann P, van Garderen KA, et al
    Treatment-associated imaging changes in newly diagnosed MGMT promoter-methylated glioblastoma undergoing chemoradiation with or without cilengitide.
    Neuro Oncol. 2024 Jan 14:noad247. doi: 10.1093.
    >> Share

  68. WEN PY, van den Bent M, Vogelbaum MA, Chang SM, et al
    RANO 2.0: The revised Response Assessment in Neuro-Oncology (RANO) criteria for high- and low-grade glial tumors in adults designed for the future.
    Neuro Oncol. 2024;26:2-4.
    >> Share

  69. DOHERTY C, Wilbanks B, Khatua S, Maher LJ 3rd, et al
    Aptamers in neuro-oncology: An emerging therapeutic modality.
    Neuro Oncol. 2024;26:38-54.
    >> Share

  70. XING B, Lei Z, Wang Z, Wang Q, et al
    A disintegrin and metalloproteinase 22 activates integrin beta1 through its disintegrin domain to promote the progression of pituitary adenoma.
    Neuro Oncol. 2024;26:137-152.
    >> Share

  71. BHUTADA I, Khambati F, Cheng SY, Tiek DM, et al
    CDK7 and CDK9 inhibition interferes with transcription, translation, and stemness, and induces cytotoxicity in GBM irrespective of temozolomide sensitivity.
    Neuro Oncol. 2024;26:70-84.
    >> Share


  72. Correction to: TSPO deficiency induces mitochondrial dysfunction, leading to hypoxia, angiogenesis, and a growth-promoting metabolic shift toward glycolysis in glioblastoma.
    Neuro Oncol. 2024 Jan 4:noad251. doi: 10.1093.
    >> Share

  73. ALBERT NL, Preusser M
    Measure what is measurable: PET RANO 1.0 criteria for interpretation of amino acid PET of diffuse gliomas.
    Neuro Oncol. 2024 Jan 2:noad228. doi: 10.1093.
    >> Share

  74. KARSCHNIA P, Dono A, Young JS, Juenger ST, et al
    Associations between recurrence patterns and outcome in glioblastoma patients undergoing re-resection: A complementary report of the RANO resect group.
    Neuro Oncol. 2024 Jan 2:noad237. doi: 10.1093.
    >> Share

    December 2023
  75. NEFF C, Price M, Cioffi G, Waite KA, et al
    The impact of the COVID-19 pandemic on treatment patterns in glioblastoma.
    Neuro Oncol. 2023 Dec 30:noad234. doi: 10.1093.
    >> Share

  76. LIU D, Zhu H, Cheng L, Li R, et al
    Hypoxia induced Galectin-8 maintains stemness in glioma stem cells via autophagy regulation.
    Neuro Oncol. 2023 Dec 30:noad264. doi: 10.1093.
    >> Share

  77. FOLTYN-DUMITRU M, Kessler T, Sahm F, Wick W, et al
    Cluster-based prognostication in glioblastoma: Unveiling heterogeneity based on diffusion and perfusion similarities.
    Neuro Oncol. 2023 Dec 28:noad259. doi: 10.1093.
    >> Share

  78. OBACZ J, Archambeau J, Lafont E, Nivet M, et al
    IRE1 endoribonuclease signaling promotes myeloid cell infiltration in glioblastoma.
    Neuro Oncol. 2023 Dec 28:noad256. doi: 10.1093.
    >> Share

  79. RALEIGH DR
    Radiotherapy dose escalation for high-risk meningiomas after subtotal resection.
    Neuro Oncol. 2023 Dec 28:noad262. doi: 10.1093.
    >> Share

  80. MUELLER S, Fangusaro J, Thomas AO, Jacques TS, et al
    Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group.
    Neuro Oncol. 2023 Dec 26:noad227. doi: 10.1093.
    >> Share

  81. YAN S, Melnick K, He X, Lyu T, et al
    Developing a computable phenotype for glioblastoma.
    Neuro Oncol. 2023 Dec 23:noad249. doi: 10.1093.
    >> Share

  82. DE SAUVAGE MA, Torrini C, Nieblas-Bedolla E, Summers E, et al
    The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis.
    Neuro Oncol. 2023 Dec 22:noad248. doi: 10.1093.
    >> Share

  83. MUELLER S, Kline C, Franson A, van der Lugt J, et al
    Rational combination platform trial design for children and young adults with Diffuse Midline Glioma: a report from PNOC.
    Neuro Oncol. 2023 Dec 20:noad181. doi: 10.1093.
    >> Share


  84. Correction to: Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?
    Neuro Oncol. 2023 Dec 18:noad241. doi: 10.1093.
    >> Share

  85. DUN MD, Odia Y, Arrillaga-Romany I
    Diffuse midline glioma, H3K27-altered: Illuminating the dark side of the moon.
    Neuro Oncol. 2023 Dec 18:noad245. doi: 10.1093.
    >> Share

  86. VAN DEN BENT M, Saratsis AM, Geurts M, Franceschi E, et al
    H3 K27M-altered Glioma and Diffuse Intrinsic Pontine Glioma: Semi-systematic Review of Treatment Landscape and Future Directions.
    Neuro Oncol. 2023 Dec 15:noad220. doi: 10.1093.
    >> Share

  87. PATEL J, Aittaleb R, Doherty R, Gera A, et al
    Liquid Biopsy in H3K27M Diffuse Midline Glioma.
    Neuro Oncol. 2023 Dec 14:noad229. doi: 10.1093.
    >> Share

  88. PUGAZENTHI S, Price M, De La Vega Gomar R, Kruchko C, et al
    Association of County-Level Socioeconomic Status with Meningioma Incidence and Outcomes.
    Neuro Oncol. 2023 Dec 13:noad223. doi: 10.1093.
    >> Share

  89. KIM D, Ko HY, Chung JI, Park YM, et al
    Visualizing Cancer-Originating Acetate Uptake Through MCT1 in Reactive Astrocytes in the Glioblastoma Tumor Microenvironment.
    Neuro Oncol. 2023 Dec 12:noad243. doi: 10.1093.
    >> Share

  90. DENG MY, Maas SLN, Hinz F, Karger CP, et al
    Efficacy and toxicity of bimodal radiotherapy in WHO grade 2 meningiomas following subtotal resection with carbon ion boost: prospective phase 2 MARCIE trial.
    Neuro Oncol. 2023 Dec 11:noad244. doi: 10.1093.
    >> Share

  91. ALBERT NL, Furtner J, van den Bent MJ, Preusser M, et al
    The potential of amino acid PET imaging for prediction and monitoring of vorasidenib response in IDH-mutant gliomas.
    Neuro Oncol. 2023 Dec 9:noad240. doi: 10.1093.
    >> Share

  92. ZHANG J, Liu B, Xu C, Ji C, et al
    Cholesterol homeostasis confers glioma malignancy triggered by hnRNPA2B1-dependent regulation of SREBP2 and LDLR.
    Neuro Oncol. 2023 Dec 9:noad233. doi: 10.1093.
    >> Share

  93. KIM AE, Lou KW, Giobbie-Hurder A, Chang K, et al
    Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance.
    Neuro Oncol. 2023 Dec 9:noad236. doi: 10.1093.
    >> Share

  94. SUN Y, Mu G, Zhang X, Wu Y, et al
    Metabolic Modulation of Histone Acetylation Mediated by HMGCL Activates the FOXM1/beta-catenin Pathway in Glioblastoma.
    Neuro Oncol. 2023 Dec 9:noad232. doi: 10.1093.
    >> Share

  95. NABORS B, Portnow J, Hattangadi-Gluth J, Horbinski C, et al
    NCCN CNS tumor guidelines update for 2023.
    Neuro Oncol. 2023;25:2114-2116.
    >> Share

  96. KARSCHNIA P, Arrillaga-Romany IC, Eichler A, Forst DA, et al
    Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.
    Neuro Oncol. 2023;25:2239-2249.
    >> Share

  97. BOELDERS SM, Gehring K, Postma EO, Rutten GJM, et al
    Cognitive functioning in untreated glioma patients: the limited predictive value of clinical variables.
    Neuro Oncol. 2023 Dec 1:noad221. doi: 10.1093.
    >> Share

    November 2023
  98. XIN DE, Liao Y, Rao R, Ogurek S, et al
    Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.
    Neuro Oncol. 2023 Nov 27:noad222. doi: 10.1093.
    >> Share

  99. CHEN E, Ling AL, Reardon DA, Chiocca EA, et al
    Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?
    Neuro Oncol. 2023 Nov 23:noad211. doi: 10.1093.
    >> Share

  100. RALEIGH DR, Preusser M
    A 34-gene expression biomarker predicts meningioma outcomes and radiotherapy responses.
    Neuro Oncol. 2023 Nov 15:noad212. doi: 10.1093.
    >> Share

  101. FANGUSARO J, Jones DT, Packer RJ, Gutmann DH, et al
    Pediatric low-grade glioma: State-of-the-art and ongoing challenges.
    Neuro Oncol. 2023 Nov 7:noad195. doi: 10.1093.
    >> Share

  102. TURCAN S
    SIRT2 inhibition as the Achilles' heel of ATRX-deficient gliomas.
    Neuro Oncol. 2023 Nov 6:noad217. doi: 10.1093.
    >> Share

  103. LING AL, Chiocca EA
    Oncolytic immunoactivation associates with survival in a glioblastoma clinical trial.
    Neuro Oncol. 2023 Nov 6:noad216. doi: 10.1093.
    >> Share

  104. ZHENG J, Wang L, Zhao S, Zhang W, et al
    TREM2 mediates MHCII-associated CD4+ T cell response against gliomas.
    Neuro Oncol. 2023 Nov 6:noad214. doi: 10.1093.
    >> Share

  105. DERBY S, Dutton L, Strathdee KE, Stevenson K, et al
    Inhibition of ATR opposes glioblastoma invasion through disruption of cytoskeletal networks and integrin internalisation via macropinocytosis.
    Neuro Oncol. 2023 Nov 4:noad210. doi: 10.1093.
    >> Share

  106. DESISTO J, Donson AM, Griesinger AM, Fu R, et al
    Tumor and immune cell types interact to produce heterogeneous phenotypes of pediatric high grade glioma.
    Neuro Oncol. 2023 Nov 2:noad207. doi: 10.1093.
    >> Share


  107. Erratum to: EPIC-1042 as a potent PTRF/Cavin1-caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma.
    Neuro Oncol. 2023 Nov 1:noad200. doi: 10.1093.
    >> Share

    October 2023
  108. SIEBENGA FF, van der Weide HL, Gelmers F, Rakers SE, et al
    Emotion recognition in relation to tumor characteristics in patients with low-grade glioma.
    Neuro Oncol. 2023 Oct 31:noad209. doi: 10.1093.
    >> Share

  109. HOTCHKISS KM, Cho E, Khasraw M
    A FIRST-IN-HUMAN PEPTIDE VACCINE TARGETING H3K27M; Encouraging Early Findings in Eight Adults with Diffuse Midline Glioma.
    Neuro Oncol. 2023 Oct 31:noad203. doi: 10.1093.
    >> Share

  110. COSENZA-CONTRERAS M, Schafer A, Sing J, Cook L, et al
    Proteometabolomics of initial and recurrent glioblastoma highlights an increased immune cell signature with altered lipid metabolism.
    Neuro Oncol. 2023 Oct 26:noad208. doi: 10.1093.
    >> Share

  111. GERSHON R, Polevikov A, Karepov Y, Shenkar A, et al
    ;Frequencies of four Tumor-infiltrating lymphocytes potently predict survival in glioblastoma, an immune desert.
    Neuro Oncol. 2023 Oct 23:noad204. doi: 10.1093.
    >> Share

  112. LEE JO, Ahn SS, Choi KS, Lee J, et al
    Added Prognostic Value of 3D Deep Learning-Derived Features from Preoperative MRI for Adult-type Diffuse Gliomas.
    Neuro Oncol. 2023 Oct 19:noad202. doi: 10.1093.
    >> Share

  113. MCDONALD MF, Hossain A, Momin E, Hasan I, et al
    Tumor-specific Polycistronic miRNA Delivered by Engineered Exosomes for the Treatment of Glioblastoma.
    Neuro Oncol. 2023 Oct 17:noad199. doi: 10.1093.
    >> Share

  114. ECKHARDT A, Drexler R, Schoof M, Struve N, et al
    Mean global DNA methylation serves as independent prognostic marker in IDH wild type glioblastoma.
    Neuro Oncol. 2023 Oct 11:noad197. doi: 10.1093.
    >> Share

  115. SARATSIS AM, Knowles T, Petrovic A, Nazarian J, et al
    H3K27M Mutant Glioma: Disease Definition and Biological Underpinnings.
    Neuro Oncol. 2023 Oct 11:noad164. doi: 10.1093.
    >> Share


  116. Corrigendum to: Isocitrate dehydrogenase wt and IDHmut adult-type diffuse gliomas display distinct alterations in ribosome biogenesis and 2'O-methylation of ribosomal RNA.
    Neuro Oncol. 2023 Oct 10:noad192. doi: 10.1093.
    >> Share

  117. LOUGHAN AR, Lanoye A, Willis KD, Fox A, et al
    Telehealth group Cognitive Behavioral Therapy for Insomnia (CBT-I) in primary brain tumor: Primary outcomes from a single-arm Phase 2 feasibility and proof-of-concept trial.
    Neuro Oncol. 2023 Oct 5:noad193. doi: 10.1093.
    >> Share

  118. OSTROM QT, Price M, Neff C, Cioffi G, et al
    CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020.
    Neuro Oncol. 2023;25.
    >> Share

  119. HANSFORD JR, Eisenstat DD
    No safe harbors for recurrent posterior fossa group A ependymoma: A time for change in risk assignment?
    Neuro Oncol. 2023;25:1868-1870.
    >> Share

  120. DONSON AM, Bertrand KC, Riemondy KA, Gao D, et al
    Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: A multicenter study.
    Neuro Oncol. 2023;25:1854-1867.
    >> Share

    September 2023
  121. BOSKOVIC P, Wilke N, Man KH, Lichter P, et al
    BCAT1 regulates glioblastoma cell plasticity and contributes to immunosuppression.
    Neuro Oncol. 2023 Sep 28:noad190. doi: 10.1093.
    >> Share

  122. KRESBACH C, Holst L, Schoof M, Leven T, et al
    Intraventricular SHH inhibition proves efficient in SHH medulloblastoma mouse model and prevents systemic side effects.
    Neuro Oncol. 2023 Sep 28:noad191. doi: 10.1093.
    >> Share

  123. REMES TM, Suo-Palosaari MH, Arikoski PM, Harila M, et al
    Radiotherapy-induced vascular cognitive impairment 20 years after childhood brain tumor.
    Neuro Oncol. 2023 Sep 27:noad186. doi: 10.1093.
    >> Share

  124. SAIJO A, Ogino H, Butowski NA, Tedesco MR, et al
    A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas.
    Neuro Oncol. 2023 Sep 27:noad185. doi: 10.1093.
    >> Share


  125. Correction to: Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.
    Neuro Oncol. 2023 Sep 26:noad180. doi: 10.1093.
    >> Share

  126. BIHN JR, Cioffi G, Waite KA, Kruchko C, et al
    Brain Tumors in United States Military Veterans.
    Neuro Oncol. 2023 Sep 22:noad182. doi: 10.1093.
    >> Share

  127. ODDE D
    Glioblastoma Cell Invasion: Go? Grow? Yes.
    Neuro Oncol. 2023 Sep 22:noad178. doi: 10.1093.
    >> Share

  128. MILDE T, Fangusaro J, Fisher MJ, Hawkins C, et al
    Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation.
    Neuro Oncol. 2023 Sep 21:noad125. doi: 10.1093.
    >> Share

  129. DESHPANDE K, Martirosian V, Nakamura BN, Das D, et al
    SRRM4-mediated REST to REST4 dysregulation promotes tumor growth and neural adaptation in breast cancer leading to brain metastasis.
    Neuro Oncol. 2023 Sep 16:noad175. doi: 10.1093.
    >> Share

  130. KRAMER C, Kilian M, Chih YC, Kourtesakis A, et al
    NLGN4X TCR transgenic T cells to treat gliomas.
    Neuro Oncol. 2023 Sep 16:noad172. doi: 10.1093.
    >> Share

  131. JOHNSON TS, MacDonald TJ, Pacholczyk R, Aguilera D, et al
    Indoximod-based chemo-immunotherapy for pediatric brain tumors: a first-in-children phase 1 trial.
    Neuro Oncol. 2023 Sep 16:noad174. doi: 10.1093.
    >> Share

  132. TOBOCHNIK S, Dorotan MKC, Ghosh HS, Lapinskas E, et al
    Glioma genetic profiles associated with electrophysiologic hyperexcitability.
    Neuro Oncol. 2023 Sep 15:noad176. doi: 10.1093.
    >> Share

  133. MISHRA DK, Popovski D, Morris SM, Bondoc A, et al
    Preclinical Pediatric Brain Tumor Models for Immunotherapy: Hurdles and a Way Forward.
    Neuro Oncol. 2023 Sep 15:noad170. doi: 10.1093.
    >> Share


  134. Correction to: HGG-16. COMPARATIVE ANALYSIS OF AUTOPHAGY IN DRUG RESPONSES AND AGGRESSIVE BEHAVIOR OF ADULT VERSUS PEDIATRIC GLIOMA CELL LINES.
    Neuro Oncol. 2023 Sep 13:noad168. doi: 10.1093.
    >> Share

  135. BRUSCHI M, Midjek L, Ajlil Y, Vairy S, et al
    Diffuse Midline Glioma Invasion and Metastasis Rely on Cell-autonomous Signaling.
    Neuro Oncol. 2023 Sep 13:noad161. doi: 10.1093.
    >> Share


  136. Correction to: Mapping pediatric brain tumors to their origins in the developing cerebellum.
    Neuro Oncol. 2023 Sep 12:noad167. doi: 10.1093.
    >> Share

  137. AVILA EK, Tobochnik S, Inati SK, Koekkoek JAF, et al
    Brain tumor-related epilepsy management: A Society for Neuro-oncology (SNO) consensus review on current management.
    Neuro Oncol. 2023 Sep 12:noad154. doi: 10.1093.
    >> Share

  138. SHI DD, Kaelin WG
    The INDIGO Trial: Precision Medicine Finally Comes to Glioma.
    Neuro Oncol. 2023 Sep 12:noad162. doi: 10.1093.
    >> Share

  139. CAHILL DP, Dunn GP
    Considering the Extent of Resection in Diffuse Glioma.
    Neuro Oncol. 2023 Sep 7:noad165. doi: 10.1093.
    >> Share

  140. BROWN AL, Sok P, Raghubar KP, Lupo PJ, et al
    Genetic susceptibility to cognitive decline following craniospinal irradiation for pediatric central nervous system tumors.
    Neuro Oncol. 2023;25:1698-1708.
    >> Share

  141. CHARBONNEAU M, Harper K, Brochu-Gaudreau K, Perreault A, et al
    The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors.
    Neuro Oncol. 2023;25:1605-1616.
    >> Share

  142. KARSCHNIA P, Dietrich J, Bruno F, Dono A, et al
    Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement ('low grade appearance') - a report of the RANO resect group.
    Neuro Oncol. 2023 Sep 4:noad160. doi: 10.1093.
    >> Share

    August 2023
  143. HONG B, Yang E, Su D, Ju J, et al
    EPIC-1042 as a potent PTRF/Cavin1-Caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for Glioblastoma.
    Neuro Oncol. 2023 Aug 31:noad159. doi: 10.1093.
    >> Share

  144. PINSON H, Silversmit G, Vanhauwaert D, Vanschoenbeek K, et al
    Epidemiology and survival of adult-type diffuse glioma in Belgium during the molecular era.
    Neuro Oncol. 2023 Aug 31:noad158. doi: 10.1093.
    >> Share

  145. MALGULWAR PB, Danussi C, Dharmaiah S, Johnson W, et al
    Sirtuin 2 inhibition modulates chromatin landscapes genome-wide to induce senescence in ATRX-deficient malignant glioma.
    Neuro Oncol. 2023 Aug 25:noad155. doi: 10.1093.
    >> Share

  146. GU D, You H, Gao J, You Y, et al
    Reply to "Targeting cholesterol homeostasis through inhibiting: An Achilles' heel for glioblastoma?".
    Neuro Oncol. 2023 Aug 25:noad146. doi: 10.1093.
    >> Share

  147. SUN Y, Mu G, Xue Z, Wang S, et al
    Targeting cholesterol homeostasis through inhibiting SREBP-2: An Achilles' heel for glioblastoma.
    Neuro Oncol. 2023 Aug 25:noad145. doi: 10.1093.
    >> Share

  148. HUANG W, Li J, Zhu H, Qin X, et al
    A novel EGFR variant EGFRx maintains glioblastoma stem cells through STAT5.
    Neuro Oncol. 2023 Aug 24:noad153. doi: 10.1093.
    >> Share

  149. KAN P, Srinivasan VM, Gumin J, Garcia R, et al
    Development of a Rabbit Human Glioblastoma Model for Testing of Endovascular Selective Intra-Arterial Infusion (ESIA) of Novel Stem Cell-Based Therapeutics.
    Neuro Oncol. 2023 Aug 21:noad152. doi: 10.1093.
    >> Share

  150. PATEL KS, Yao J, Cho NS, Sanvito F, et al
    pH-Weighted Amine Chemical Exchange Saturation Transfer Echo Planar Imaging (CEST-EPI) Visualizes Infiltrating Glioblastoma Cells.
    Neuro Oncol. 2023 Aug 18:noad150. doi: 10.1093.
    >> Share

  151. FRANCIS SS, Guerra G, Hansen HM, Wendt G, et al
    Inherited polymorphisms in the Human Leukocyte Antigen Region modify the association between varicella-zoster virus antibody reactivity and glioma prognosis.
    Neuro Oncol. 2023 Aug 18:noad122. doi: 10.1093.
    >> Share

  152. GALLO M
    Prognostic value of integrative genomic approaches for IDH-mutant gliomas.
    Neuro Oncol. 2023 Aug 17:noad151. doi: 10.1093.
    >> Share

  153. JACKSON ER, Persson ML, Fish CJ, Findlay IJ, et al
    A review of the anti-tumor potential of current therapeutics targeting the mitochondrial protease ClpP in H3K27-altered, diffuse midline glioma.
    Neuro Oncol. 2023 Aug 17:noad144. doi: 10.1093.
    >> Share

  154. SHENOY G, Connor JR
    A Closer Look at the Role of Iron in Glioblastoma.
    Neuro Oncol. 2023 Aug 4:noad136. doi: 10.1093.
    >> Share

  155. OKONECHNIKOV K, Joshi P, Sepp M, Leiss K, et al
    Mapping pediatric brain tumors to their origins in the developing cerebellum.
    Neuro Oncol. 2023 Aug 3:noad124. doi: 10.1093.
    >> Share

  156. ROBERTS KF, Dahiya SM
    Mitotic index is (still) important for grading isocitrate dehydrogenase (IDH)-mutant astrocytoma.
    Neuro Oncol. 2023;25:1450-1451.
    >> Share

  157. FENG J, Duan Z, Yao K, Gui Q, et al
    Primary papillary epithelial tumor of the sella and posterior pituitary tumor show similar (epi)genetic features and constitute a single neuro-oncological entity.
    Neuro Oncol. 2023;25:1487-1497.
    >> Share

  158. KOJIC M, Maybury MK, Waddell N, Koufariotis LT, et al
    Efficient detection and monitoring of pediatric brain malignancies with liquid biopsy based on patient-specific somatic mutation screening.
    Neuro Oncol. 2023;25:1507-1517.
    >> Share

  159. KROS JM, Rushing E, Uwimana AL, Hernandez-Lain A, et al
    Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033.
    Neuro Oncol. 2023;25:1443-1449.
    >> Share

  160. ZUCCATO JA, Patil V, Mansouri S, Voisin M, et al
    Cerebrospinal fluid methylome-based liquid biopsies for accurate malignant brain neoplasm classification.
    Neuro Oncol. 2023;25:1452-1460.
    >> Share

  161. PARAQINDES H, Mourksi NE, Ballesta S, Hedjam J, et al
    IDHwt and IDHmut adult-type diffuse gliomas display distinct alterations in ribosome biogenesis and 2'O-methylation of ribosomal RNA.
    Neuro Oncol. 2023 Aug 2:noad140. doi: 10.1093.
    >> Share

  162. APFELBAUM A, Bandopadhayay P
    The 'LOGGIC' of RNA-sequencing in enhancing diagnoses of pediatric low-grade gliomas.
    Neuro Oncol. 2023 Aug 2:noad142. doi: 10.1093.
    >> Share


  163. Corrigendum to: USP36 promotes tumorigenesis and drug sensitivity of glioblastoma by deubiquitinating and stabilizing ALKBH5.
    Neuro Oncol. 2023 Aug 1:noad135. doi: 10.1093.
    >> Share

  164. MONJE M, Cooney T, Glod J, Huang J, et al
    A Phase I Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium (PBTC-047).
    Neuro Oncol. 2023 Aug 1:noad141. doi: 10.1093.
    >> Share

    July 2023
  165. ROTH P
    CARs in the brain: can we tackle glioblastoma with engineered NK cells?
    Neuro Oncol. 2023 Jul 31:noad131. doi: 10.1093.
    >> Share

  166. CHIANG J, Bagchi A, Li X, Dhanda SK, et al
    High-grade glioma in infants and young children is histologically, molecularly, and clinically diverse-Results from the SJYC07 trial and institutional experience.
    Neuro Oncol. 2023 Jul 28:noad130. doi: 10.1093.
    >> Share

  167. YOUNG JS, Morshed RA, Hervey-Jumper SL, Berger MS, et al
    The Surgical Management of Diffuse Gliomas: Current State of Neurosurgical Management and Future Directions.
    Neuro Oncol. 2023 Jul 27:noad133. doi: 10.1093.
    >> Share

  168. LIU RZ, Choi WS, Jain S, Xu X, et al
    Stationary-to-migratory transition in glioblastoma stem-like cells driven by a FABP7-RXRalpha neurogenic pathway.
    Neuro Oncol. 2023 Jul 27:noad134. doi: 10.1093.
    >> Share

  169. WOLIN AR, Vincent MY, Hotz T, Purdy SC, et al
    EYA2 Tyrosine Phosphatase Inhibition Reduces MYC and Prevents Medulloblastoma Progression.
    Neuro Oncol. 2023 Jul 24:noad128. doi: 10.1093.
    >> Share

  170. HALL MD, Kotecha R
    Social Determinants of Health: A Forgotten Risk Factor for Neurocognition in Pediatric Brain Tumor Survivors.
    Neuro Oncol. 2023 Jul 24:noad127. doi: 10.1093.
    >> Share

  171. PREUSSER M, Geurts M, Hainfellner JA, van den Bent MJ, et al
    What is an isocitrate dehydrogenase-mutated central nervous system World Health Organization grade 2 glioma, or who should receive vorasidenib?
    Neuro Oncol. 2023 Jul 21:noad113. doi: 10.1093.
    >> Share

  172. MAMATJAN Y, Voisin M, Nassiri F, Moraes FY, et al
    Integrated molecular analysis reveals hypermethylation and overexpression of HOX genes to be poor prognosticators in IDH mutant glioma.
    Neuro Oncol. 2023 Jul 20:noad126. doi: 10.1093.
    >> Share

  173. HOU J, Huang P, Xu M, Wang H, et al
    NCAPG promotes the progression of glioblastoma by facilitating PARP1-mediated E2F1 transactivation.
    Neuro Oncol. 2023 Jul 9:noad111. doi: 10.1093.
    >> Share

  174. LAPRIE A, Noel G, Chaltiel L, Truc G, et al
    Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial).
    Neuro Oncol. 2023 Jul 7:noad119. doi: 10.1093.
    >> Share

  175. CHANG SM
    Increasing growth and impact of Neuro-Oncology.
    Neuro Oncol. 2023;25:1199.
    >> Share


  176. Erratum to: METB-13. A SINGLE-CELL GENETIC IN VIVO LINEAGE-TRACING PLATFORM FOR MEDULLOBLASTOMA.
    Neuro Oncol. 2023 Jul 6:noad116. doi: 10.1093.
    >> Share

  177. POON MTC, Piper RJ, Thango N, Fountain DM, et al
    Variation in postoperative outcomes of patients with intracranial tumors: insights from a prospective international cohort study during the COVID-19 pandemic.
    Neuro Oncol. 2023;25:1299-1309.
    >> Share

  178. WELLER M, Le Rhun E, Van den Bent M, Chang SM, et al
    Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults.
    Neuro Oncol. 2023;25:1200-1224.
    >> Share

  179. TRAGER M, Schweizer L, Perez E, Schmid S, et al
    Adult intracranial ependymoma-relevance of DNA methylation profiling for diagnosis, prognosis, and treatment.
    Neuro Oncol. 2023;25:1286-1298.
    >> Share

  180. RAMMOHAN N, Ho A, Besson P, Kruser TJ, et al
    Whole-brain radiotherapy associated with structural changes resembling aging as determined by anatomic surface-based deep learning.
    Neuro Oncol. 2023;25:1323-1330.
    >> Share

  181. SMOLL NR, Brady Z, Scurrah KJ, Lee C, et al
    Computed tomography scan radiation and brain cancer incidence.
    Neuro Oncol. 2023;25:1368-1376.
    >> Share

  182. NOCH EK, Palma LN, Yim I, Bullen N, et al
    Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma.
    Neuro Oncol. 2023 Jul 3:noad117. doi: 10.1093.
    >> Share

    June 2023
  183. VAN SCHAIK J, Schouten-van Meeteren AYN, Vos-Kerkhof E, Janssens GO, et al
    Treatment and outcome of the Dutch Childhood Craniopharyngioma Cohort study; first results after centralization of care.
    Neuro Oncol. 2023 Jun 29:noad112. doi: 10.1093.
    >> Share

  184. ZHAO Y, Gu S, Li L, Zhao R, et al
    A novel risk signature for predicting brain metastasis in patients with lung adenocarcinoma.
    Neuro Oncol. 2023 Jun 28:noad115. doi: 10.1093.
    >> Share

  185. KOLODZIEJCZAK AS, Guerrini-Rousseau L, Planchon JM, Ecker J, et al
    Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome.
    Neuro Oncol. 2023 Jun 28:noad114. doi: 10.1093.
    >> Share

  186. HANSCH L, Peipp M, Mastall M, Villars D, et al
    Chimeric antigen receptor (CAR) T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma.
    Neuro Oncol. 2023 Jun 19:noad108. doi: 10.1093.
    >> Share

  187. RATLIFF M, Karimian-Jazi K, Hoffmann DC, Rauschenbach L, et al
    Individual glioblastoma cells harbor both proliferative and invasive capabilities during tumor progression.
    Neuro Oncol. 2023 Jun 19:noad109. doi: 10.1093.
    >> Share

  188. KOCAKAVUK E, Johnson KC, Sabedot TS, Reinhardt HC, et al
    Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas.
    Neuro Oncol. 2023 Jun 17:noad095. doi: 10.1093.
    >> Share

  189. CHAN P, Rich JN, Kay SA
    Watching the Clock in Glioblastoma.
    Neuro Oncol. 2023 Jun 16:noad107. doi: 10.1093.
    >> Share

  190. MUELLER S, Kline C, Stoller S, Lundy S, et al
    PNOC015: Repeated convection enhanced delivery (CED) of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
    Neuro Oncol. 2023 Jun 15:noad105. doi: 10.1093.
    >> Share

  191. HOTCHKISS KM, Batich KA, Mohan A, Rahman R, et al
    Dendritic cell vaccine trials in gliomas: Untangling the lines.
    Neuro Oncol. 2023 Jun 8:noad088. doi: 10.1093.
    >> Share

  192. KULIESIUTE U, Joseph K, Straehle J, Ravi VM, et al
    Sialic acid metabolism orchestrates transcellular connectivity and signalling in glioblastoma.
    Neuro Oncol. 2023 Jun 8:noad101. doi: 10.1093.
    >> Share

  193. HUANG N, Chen Z, Yang X, Gao Y, et al
    Upstream Open Reading Frame-encoded MP31 Disrupts the Mitochondrial Quality Control Process and Inhibits Tumorigenesis in Glioblastoma.
    Neuro Oncol. 2023 Jun 6:noad099. doi: 10.1093.
    >> Share

  194. XIN L, Tan Y, Zhu Y, Cui X, et al
    EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT.
    Neuro Oncol. 2023 Jun 5:noad102. doi: 10.1093.
    >> Share

  195. BAILLEUL J, Ruan Y, Abdulrahman L, Scott AJ, et al
    PKM2 rewires glucose metabolism during radiation therapy to promote an antioxidant response and glioblastoma radioresistance.
    Neuro Oncol. 2023 Jun 5:noad103. doi: 10.1093.
    >> Share

  196. SAHM F, Brandner S, Bertero L, Capper D, et al
    Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline.
    Neuro Oncol. 2023 Jun 2:noad100. doi: 10.1093.
    >> Share

  197. ALI UM, Withrow DR, Judge AD, Plaha P, et al
    Temporal trends in the incidence of malignant and nonmalignant primary brain and central nervous system tumors by the method of diagnosis in England, 1993-2017.
    Neuro Oncol. 2023;25:1177-1192.
    >> Share

  198. SUN T, Wang Y, Liu X, Li Z, et al
    Deep learning based on preoperative magnetic resonance (MR) images improves the predictive power of survival models in primary spinal cord astrocytomas.
    Neuro Oncol. 2023;25:1157-1165.
    >> Share

  199. ZAYTSEVA M, Valiakhmetova A, Yasko L, Samarin A, et al
    Molecular heterogeneity of pediatric choroid plexus carcinomas determines the distinctions in clinical course and prognosis.
    Neuro Oncol. 2023;25:1132-1145.
    >> Share

  200. DEMIRDIZEN E, Al-Ali R, Narayanan A, Sun X, et al
    TRIM67 drives tumorigenesis in oligodendrogliomas through Rho GTPase-dependent membrane blebbing.
    Neuro Oncol. 2023;25:1031-1043.
    >> Share

  201. LAMBA N, Cagney DN, Catalano PJ, Kim D, et al
    A Genomic Score to Predict Local Control among Patients with Brain Metastases Managed with Radiation.
    Neuro Oncol. 2023 Jun 1:noad098. doi: 10.1093.
    >> Share

    May 2023
  202. KARSCHNIA P, Dono A, Young JS, Juenger ST, et al
    Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group.
    Neuro Oncol. 2023 May 30:noad074. doi: 10.1093.
    >> Share


  203. Correction to: Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma.
    Neuro Oncol. 2023 May 29:noad091. doi: 10.1093.
    >> Share


  204. Corrigendum to: Identifying risk factors for recurrence/relapse in NF1 optic pathway gliomas: Moving forward by looking back.
    Neuro Oncol. 2023 May 25:noad093. doi: 10.1093.
    >> Share


  205. Correction to: Progress for patients with melanoma brain metastases.
    Neuro Oncol. 2023 May 19:noad089. doi: 10.1093.
    >> Share


  206. Corrigendum to: Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1.
    Neuro Oncol. 2023 May 19:noad094. doi: 10.1093.
    >> Share

  207. NEHAMA D, Woodell AS, Maingi SM, Hingtgen SD, et al
    Cell-based therapies for glioblastoma: Promising tools against tumor heterogeneity.
    Neuro Oncol. 2023 May 14:noad092. doi: 10.1093.
    >> Share


  208. Retraction of: PTEN loss drives resistance to the neddylation inhibitor MLN4924 in glioblastoma and can be overcome with TOP2A inhibitors.
    Neuro Oncol. 2023 May 13:noad081. doi: 10.1093.
    >> Share

  209. HAASE S, Lowenstein PR, Castro MG
    "Sabotaging the Protein Factory to Overcome Glioma Stem Cell Resistance".
    Neuro Oncol. 2023 May 13:noad090. doi: 10.1093.
    >> Share

  210. DI NUNNO V, Gatto L, Tosoni A, Bartolini S, et al
    Letter concerning "Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival": Toward surrogate endpoints for phase II trials in patients with recurrent gliobla
    Neuro Oncol. 2023 May 12:noad071. doi: 10.1093.
    >> Share

  211. ELLINGSON BM, Wen PY, Cloughesy TF
    Reply to Di Nunno et al. concerning objective response rates targets for recurrent glioblastoma clinical trials: Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma.
    Neuro Oncol. 2023 May 11:noad085. doi: 10.1093.
    >> Share

  212. BURGER MC, Forster MT, Romanski A, Strassheimer F, et al
    Intracranial injection of NK cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma.
    Neuro Oncol. 2023 May 6:noad087. doi: 10.1093.
    >> Share

  213. LAMBA N, Cagney DN, Catalano PJ, Elhalawani H, et al
    Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries.
    Neuro Oncol. 2023;25:973-983.
    >> Share

  214. ALLEN BD, Alaghband Y, Kramar EA, Ru N, et al
    Elucidating the neurological mechanism of the FLASH effect in juvenile mice exposed to hypofractionated radiotherapy.
    Neuro Oncol. 2023;25:927-939.
    >> Share

  215. HUANG J, Chan SC, Lok V, Zhang L, et al
    Disease burden, risk factors, and trends of primary central nervous system (CNS) cancer: A global study of registries data.
    Neuro Oncol. 2023;25:995-1005.
    >> Share

    April 2023
  216. JO J, Diaz M, Horbinski C, Mackman N, et al
    Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review.
    Neuro Oncol. 2023 Apr 26:noad059. doi: 10.1093.
    >> Share

  217. MULE' TN, Hodges J, Wu S, Li Y, et al
    Social Determinants of Cognitive Outcomes in Survivors of Pediatric Brain Tumors Treated with Conformal Radiation Therapy.
    Neuro Oncol. 2023 Apr 26:noad080. doi: 10.1093.
    >> Share

  218. KOEKKOEK JAF, van der Meer PB, Walbert T
    Reply to the letter regarding "Palliative care and end-of-life care in adults with malignant brain tumors".
    Neuro Oncol. 2023 Apr 25:noad069. doi: 10.1093.
    >> Share

  219. LIU G, Zhang P, Chen S, Chen Z, et al
    FAM129A promotes self-renewal and maintains invasive status via stabilizing the Notch intracellular domain in glioma stem cells.
    Neuro Oncol. 2023 Apr 21:noad079. doi: 10.1093.
    >> Share

  220. MILLER AM, Karajannis MA
    Cerebrospinal fluid: the new frontier for methylome-based diagnostic classification of brain tumors.
    Neuro Oncol. 2023 Apr 20:noad075. doi: 10.1093.
    >> Share

  221. HARDIN EC, Schmid S, Sommerkamp A, Bodden C, et al
    LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients.
    Neuro Oncol. 2023 Apr 19:noad078. doi: 10.1093.
    >> Share

  222. BARBIERI F, Bajetto A, Dellacasagrande I, Solari A, et al
    Stem-like signatures in human meningioma cells are under the control of CXCL11/CXCL12 chemokine activity.
    Neuro Oncol. 2023 Apr 19:noad076. doi: 10.1093.
    >> Share

  223. CONTRERAS-ZARATE MJ, Alvarez-Eraso KLF, Jaramillo-Gomez JA, Littrell Z, et al
    Short-term topiramate treatment prevents radiation-induced cytotoxic edema in preclinical models of breast-cancer brain metastasis.
    Neuro Oncol. 2023 Apr 13:noad070. doi: 10.1093.
    >> Share

  224. MISHIMA K, Nishikawa R, Narita Y, Mizusawa J, et al
    Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C.
    Neuro Oncol. 2023;25:687-698.
    >> Share

  225. LI X, Moreira DC, Bag AK, Qaddoumi I, et al
    The clinical and molecular characteristics of progressive hypothalamic/optic pathway pilocytic astrocytoma.
    Neuro Oncol. 2023;25:750-760.
    >> Share

  226. FU R, Norris GA, Willard N, Griesinger AM, et al
    Spatial transcriptomic analysis delineates epithelial and mesenchymal subpopulations and transition stages in childhood ependymoma.
    Neuro Oncol. 2023;25:786-798.
    >> Share

  227. SELT F, Sigaud R, Valinciute G, Sievers P, et al
    BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma.
    Neuro Oncol. 2023;25:735-747.
    >> Share

  228. STOLTZE UK, Foss-Skiftesvik J, van Overeem Hansen T, Byrjalsen A, et al
    Genetic predisposition and evolutionary traces of pediatric cancer risk: a prospective 5-year population-based genome sequencing study of children with CNS tumors.
    Neuro Oncol. 2023;25:761-773.
    >> Share


  229. Corrigendum to: NCOG-45. DIFFERENTIAL AND DOSE-DEPENDENT EFFECTS OF CRANIAL IRRADIATION ON BRAIN STRUCTURES AND NEUROPSYCHOLOGICAL OUTCOMES IN CHILDREN WITH POSTERIOR FOSSA BRAIN TUMORS TREATED WITH DIFFERENT MODALITIES.
    Neuro Oncol. 2023 Apr 1:noad058. doi: 10.1093.
    >> Share

    March 2023

  230. Corrigendum to: Association of circulating markers with cognitive decline after radiation therapy for brain metastasis.
    Neuro Oncol. 2023 Mar 29:noad062. doi: 10.1093.
    >> Share

  231. GOENKA A, Song X, Tiek D, Iglesia RP, et al
    Oncogenic Long Non-coding RNA LINC02283 Enhances PDGF Receptor A mediated Signaling and Drives Glioblastoma Tumorigenesis.
    Neuro Oncol. 2023 Mar 29:noad065. doi: 10.1093.
    >> Share

  232. XIE J, Kuriakose T, Bianski B, Twarog N, et al
    ATM inhibition enhances the efficacy of radiation across distinct molecular subgroups of pediatric high-grade glioma.
    Neuro Oncol. 2023 Mar 27:noad064. doi: 10.1093.
    >> Share

  233. WERNER JM, Wollring MM, Tscherpel C, Rosen EK, et al
    Multimodal imaging findings in patients with glioblastoma with extensive coagulative necrosis related to regorafenib.
    Neuro Oncol. 2023 Mar 24:noad051. doi: 10.1093.
    >> Share


  234. Corrigendum to: IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification.
    Neuro Oncol. 2023 Mar 21:noad048. doi: 10.1093.
    >> Share

  235. GU D, Zhou F, You H, Gao J, et al
    SREBP2 maintains glioblastoma stem cells through keeping the balance between cholesterol biosynthesis and uptake.
    Neuro Oncol. 2023 Mar 19:noad060. doi: 10.1093.
    >> Share

  236. BAUCHET L, Sanson M
    Deciphering gliomagenesis from GWAS.
    Neuro Oncol. 2023 Mar 14:noad057. doi: 10.1093.
    >> Share

  237. KUMTHEKAR PU, Avram MJ, Lassman AB, Lin NU, et al
    A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics.
    Neuro Oncol. 2023;25:557-565.
    >> Share

  238. VOLLMUTH P, Foltyn M, Huang RY, Galldiks N, et al
    Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: An international multi-reader study.
    Neuro Oncol. 2023;25:533-543.
    >> Share

  239. SPERDUTO PW, Salama AKS, Anders C
    Progress for Patients with Melanoma Brain Metastases.
    Neuro Oncol. 2023 Mar 8:noad050. doi: 10.1093.
    >> Share

  240. GROSSMAN SA
    Using Historical Objective Response Rates to Design Single Arm Phase II Trials in Patients with Recurrent Glioblastoma.
    Neuro Oncol. 2023 Mar 7:noad046. doi: 10.1093.
    >> Share

  241. YANG Y, Brown MC, Zhang G, Stevenson K, et al
    Polio Virotherapy Targets the Malignant Glioma Myeloid Infiltrate with Diffuse Microglia Activation Engulfing the CNS.
    Neuro Oncol. 2023 Mar 2:noad052. doi: 10.1093.
    >> Share

  242. DREXLER R, Gottsche J, Sauvigny T, Schuller U, et al
    Targeted anticonvulsive treatment of IDH-wildtype glioblastoma based on DNA methylation subclasses.
    Neuro Oncol. 2023 Mar 1:noad014. doi: 10.1093.
    >> Share

    February 2023
  243. ROMO CG, Piotrowski AF, Campian JL, Diarte J, et al
    Clinical, Histological and Molecular Features of Gliomas in Adults with Neurofibromatosis Type 1.
    Neuro Oncol. 2023 Feb 25:noad033. doi: 10.1093.
    >> Share

  244. FOSS-SKIFTESVIK J, Li S, Rosenbaum A, Hagen CM, et al
    Multi-ancestry genome-wide association study of 4,069 children with glioma identifies 9p21.3 risk locus.
    Neuro Oncol. 2023 Feb 22:noad042. doi: 10.1093.
    >> Share

  245. MULKEARNS-HUBERT EE, Lathia JD
    DUB-ling down on the epigenetic regulation of cancer stem cells in glioblastoma.
    Neuro Oncol. 2023 Feb 22:noad040. doi: 10.1093.
    >> Share

  246. DE ROECK L, Gillebert RC, van Aert RCM, Vanmeenen A, et al
    Cognitive outcomes after multimodal treatment in adult glioma patients: A meta-analysis.
    Neuro Oncol. 2023 Feb 21:noad045. doi: 10.1093.
    >> Share


  247. Corrigendum to: Novel cancer gene discovery using a forward genetic screen in RCAS-PDGFB-driven gliomas.
    Neuro Oncol. 2023 Feb 21:noac267. doi: 10.1093.
    >> Share

  248. BHATTACHARYYA S, Oblinger JL, Beauchamp RL, Yin Z, et al
    Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma.
    Neuro Oncol. 2023 Feb 20:noad037. doi: 10.1093.
    >> Share

  249. ROTTGERING JG, Klein M, Douw L
    Letter regarding "Palliative care and end-of-life care in adults with malignant brain tumors".
    Neuro Oncol. 2023 Feb 18:noad006. doi: 10.1093.
    >> Share

  250. LASSMAN AB, van den Bent MJ
    What is a glioblastoma?
    Neuro Oncol. 2023 Feb 15:noad044. doi: 10.1093.
    >> Share

  251. BAGLEY SJ
    Phase 2 trials in the era of glioblastoma immunotherapy: New mechanisms of action, familiar challenges in trial design and tumor response assessment.
    Neuro Oncol. 2023 Feb 15:noad043. doi: 10.1093.
    >> Share

  252. CHANG SM
    Launch of an Editorial Scholars Program for Neuro-Oncology.
    Neuro Oncol. 2023;25:219-220.
    >> Share

  253. GAO T, Zhang S, Li M
    Intrathecal trastuzumab: What else do we need to consider?
    Neuro Oncol. 2023;25:418-419.
    >> Share

  254. OBERKAMPF F, Gutierrez M, Trabelsi Grati O, Rhun EL, et al
    Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis.
    Neuro Oncol. 2023;25:365-374.
    >> Share

  255. MCAFEE SS, Zhang S, Zou P, Conklin HM, et al
    Fastigial nuclei surgical damage and focal midbrain disruption implicate PAG survival circuits in cerebellar mutism syndrome.
    Neuro Oncol. 2023;25:375-385.
    >> Share

  256. UPADHYAYA SA, Campagne O, Billups CA, Orr BA, et al
    Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor.
    Neuro Oncol. 2023;25:386-397.
    >> Share

  257. LIM YC, Jensen KE, Aguilar-Morante D, Vardouli L, et al
    Non-metabolic functions of phosphofructokinase-1 orchestrate tumor cellular invasion and genome maintenance under bevacizumab therapy.
    Neuro Oncol. 2023;25:248-260.
    >> Share

  258. GREGORY TA, Williford GL, Maronge JM, Alfaro K, et al
    An expedited strategy for accurate and timely integrated molecular diagnosis of gliomas.
    Neuro Oncol. 2023 Feb 1:noad007. doi: 10.1093.
    >> Share

  259. PATEL RV, Yao S, Huang RY, Bi WL, et al
    Application of radiomics to meningiomas: a systematic review.
    Neuro Oncol. 2023 Feb 1:noad028. doi: 10.1093.
    >> Share

    January 2023
  260. ALEMANY M, Todeschini FA, Vidal N, Pons A, et al
    The impact of health system crises on glioblastoma management and outcomes.
    Neuro Oncol. 2023 Jan 30:noac266. doi: 10.1093.
    >> Share

  261. TONN S, Korshunov A, Obrecht D, Sill M, et al
    Risk prediction in early childhood SHH medulloblastoma treated with radiation-avoiding chemotherapy: Evidence for more than two subgroups.
    Neuro Oncol. 2023 Jan 30:noad027. doi: 10.1093.
    >> Share

  262. CHEN CH, Chin RL, Hartley GP, Lea ST, et al
    Novel Murine Glioblastoma Models That Reflect the Immunotherapy Resistance Profile of Human Disease.
    Neuro Oncol. 2023 Jan 27:noad025. doi: 10.1093.
    >> Share

  263. AQUILANTI E, Kageler L, Watson J, Baird DM, et al
    Telomerase inhibition is an effective therapeutic strategy in TERT promoter mutant-glioblastoma models with low tumor volume.
    Neuro Oncol. 2023 Jan 24:noad024. doi: 10.1093.
    >> Share

  264. LIU H, Xu C, Diplas BH, Brown A, et al
    Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.
    Neuro Oncol. 2023 Jan 23:noad022. doi: 10.1093.
    >> Share

  265. AJAIB S, Lodha D, Pollock S, Hemmings G, et al
    GBMdeconvoluteR accurately infers proportions of neoplastic and immune cell populations from bulk glioblastoma transcriptomics data.
    Neuro Oncol. 2023 Jan 23:noad021. doi: 10.1093.
    >> Share

  266. WANG Z, Wang Y, Chang M, Wang Y, et al
    Single-cell transcriptomic analyses provide insights into the cellular origins and drivers of brain metastasis from lung adenocarcinoma.
    Neuro Oncol. 2023 Jan 19:noad017. doi: 10.1093.
    >> Share

  267. ALEJO S, Palacios BE, Venkata PP, He Y, et al
    Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double strand break repair and augments efficacy of temozolomide in glioblastoma.
    Neuro Oncol. 2023 Jan 18:noad018. doi: 10.1093.
    >> Share

  268. KOTECHA R, Mehta MP
    Rethinking Classification and Categorization of Resection Extent and its Impact on Patient Survival in Glioblastoma: Was Walter Dandy Ahead of His Time?
    Neuro Oncol. 2023 Jan 16:noad013. doi: 10.1093.
    >> Share

  269. SAMPSON JH, Singh Achrol A, Aghi MK, Bankiewiecz K, et al
    Targeting the IL4 Receptor with MDNA55 in Patients with Recurrent Glioblastoma: Results of a Phase 2b Trial.
    Neuro Oncol. 2023 Jan 14:noac285. doi: 10.1093.
    >> Share

  270. STERN E, Ben-Ami M, Gruber N, Toren A, et al
    Hypothalamic-Pituitary-Gonadal Function, Pubertal Development and Fertility Outcomes in Male and Female Medulloblastoma Survivors: A Single Centre Experience.
    Neuro Oncol. 2023 Jan 12:noad009. doi: 10.1093.
    >> Share

  271. CAPPER D, Reifenberger G, French PJ, Schweizer L, et al
    EANO guideline on rational molecular testing of gliomas, glioneuronal and neuronal tumors in adults for targeted therapy selection.
    Neuro Oncol. 2023 Jan 12:noad008. doi: 10.1093.
    >> Share

  272. LIGON JA, Sayour EJ
    Spotlighting cellular therapies to advance the treatment of medulloblastoma.
    Neuro Oncol. 2023 Jan 11:noad005. doi: 10.1093.
    >> Share

  273. LIU X, Kang C
    Bridging deep sequencing to precision oncology in meningiomas.
    Neuro Oncol. 2023 Jan 10:noad004. doi: 10.1093.
    >> Share


  274. Retraction of: A novel fully automated MRI-based deep-learning method for classification of IDH mutation status in brain gliomas.
    Neuro Oncol. 2023 Jan 10:noac260. doi: 10.1093.
    >> Share

  275. ZHANG H, Liu K, Ba R, Zhang Z, et al
    Histological and Molecular Classifications of Pediatric Glioma with Time-dependent Diffusion MRI based Microstructural Mapping.
    Neuro Oncol. 2023 Jan 7:noad003. doi: 10.1093.
    >> Share

  276. ELLINGSON BM, Wen PY, Chang SM, van den Bent M, et al
    Objective response rate (ORR) targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival.
    Neuro Oncol. 2023 Jan 7:noad002. doi: 10.1093.
    >> Share

  277. KOEKKOEK JAF, van der Meer PB, Pace A, Hertler C, et al
    Corrigendum to: Palliative care and end-of-life care in adults with malignant brain tumors.
    Neuro Oncol. 2023;25:212.
    >> Share

  278. FORTIN ENSIGN SP, Jenkins RB, Giannini C, Sarkaria JN, et al
    Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma.
    Neuro Oncol. 2023;25:28-36.
    >> Share

  279. HOANG-XUAN K, Deckert M, Ferreri AJM, Furtner J, et al
    European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL).
    Neuro Oncol. 2023;25:37-53.
    >> Share

  280. DE RUITER MB, Groot PFC, Deprez S, Pullens P, et al
    Hippocampal avoidance prophylactic cranial irradiation (HA-PCI) for small cell lung cancer reduces hippocampal atrophy compared to conventional PCI.
    Neuro Oncol. 2023;25:167-176.
    >> Share

  281. DE ALMEIDA MAGALHAES T, Alencastro Veiga Cruzeiro G, Ribeiro de Sousa G, Englinger B, et al
    Activation of Hedgehog signaling by the oncogenic RELA fusion reveals a primary cilia-dependent vulnerability in supratentorial ependymoma.
    Neuro Oncol. 2023;25:185-198.
    >> Share

  282. GUERRA G, McCoy L, Hansen HM, Rice T, et al
    Antibodies to varicella-zoster virus and three other herpesviruses and survival in adults with glioma.
    Neuro Oncol. 2023 Jan 4:noac283. doi: 10.1093.
    >> Share

  283. XIE Y, He L, Zhang Y, Huang H, et al
    Wnt Signaling Regulates MFSD2A-dependent Drug Delivery through Endothelial Transcytosis in Glioma.
    Neuro Oncol. 2023 Jan 2:noac288. doi: 10.1093.
    >> Share

    December 2022
  284. ZISI A, Kanellis DC, Moussaud S, Karlsson I, et al
    Small Molecule-mediated Disruption of Ribosome Biogenesis Synergizes With FGFR Inhibitors to Suppress Glioma Cell Growth.
    Neuro Oncol. 2022 Dec 30:noac286. doi: 10.1093.
    >> Share

  285. APPS JR, Martinez-Barbera JP
    A promising future for hypothalamic dysfunction in craniopharyngioma.
    Neuro Oncol. 2022 Dec 27:noac284. doi: 10.1093.
    >> Share

  286. PREUSSER M, van den Bent MJ
    Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination (DCVax-L) in glioblastoma: breakthrough or fata morgana?
    Neuro Oncol. 2022 Dec 23:noac281. doi: 10.1093.
    >> Share

  287. ALPEN K, Vajdic CM, MacInnis RJ, Milne RL, et al
    Australian genome-wide association study confirms higher female risk for adult glioma associated with variants in the region of CCDC26.
    Neuro Oncol. 2022 Dec 20:noac279. doi: 10.1093.
    >> Share

  288. STUNDON JL, Ijaz H, Gaonkar KS, Kaufman RS, et al
    ALT in Pediatric High-Grade Gliomas Can Occur without ATRX Mutation and is Enriched in Patients with Pathogenic Germline MMR Variants.
    Neuro Oncol. 2022 Dec 20:noac278. doi: 10.1093.
    >> Share

  289. IORGULESCU JB, Sun C, Neff C, Cioffi G, et al
    Corrigendum to: Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States.
    Neuro Oncol. 2022 Dec 19:noac270. doi: 10.1093.
    >> Share


  290. Corrigendum to: Integrated longitudinal analysis of adult grade 4 diffuse gliomas with long-term relapse interval revealed upregulation of TGF-beta signaling in recurrent tumors.
    Neuro Oncol. 2022 Dec 16:noac265. doi: 10.1093.
    >> Share

  291. MILLER JJ, Arrillaga-Romany I
    IDH-mutant glioma: A new IDH1 inhibitor moves forward.
    Neuro Oncol. 2022 Dec 16:noac275. doi: 10.1093.
    >> Share

  292. TAO W, Lei H, Luo W, Huang Z, et al
    NIR Drives Glioblastoma Growth by Promoting Ribosomal DNA Transcription in Glioma Stem Cells.
    Neuro Oncol. 2022 Dec 15:noac272. doi: 10.1093.
    >> Share

  293. HAO X, Bahia R, Cseh O, Bozek D, et al
    BI-907828, a novel potent MDM2 inhibitor, inhibits GBM brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models.
    Neuro Oncol. 2022 Dec 15:noac271. doi: 10.1093.
    >> Share

  294. BARNHOLTZ-SLOAN JS
    Expanding our knowledge of brain tumor overall survival trends at a global scale.
    Neuro Oncol. 2022 Dec 14:noac268. doi: 10.1093.
    >> Share

  295. HASANOV M, Milton DR, Bea Davies A, Sirmans E, et al
    Changes In Outcomes And Factors Associated With Survival In Melanoma Patients With Brain Metastases.
    Neuro Oncol. 2022 Dec 13:noac251. doi: 10.1093.
    >> Share

  296. HUNTOON K, Anderson SK, Ballman KV, Twohy E, et al
    Association of Circulating Markers with Cognitive Decline After Radiation Therapy for Brain Metastasis.
    Neuro Oncol. 2022 Dec 6:noac262. doi: 10.1093.
    >> Share

  297. MORENO V, Sepulveda JM, Reardon DA, Perez-Nunez A, et al
    Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: a phase I, "windowofopportunity" study.
    Neuro Oncol. 2022 Dec 1:noac263. doi: 10.1093.
    >> Share

  298. WANG C, Zhang H, Fan J, Li Q, et al
    Inhibition of integrated stress response protects against lipid-induced senescence in hypothalamic neural stem cells in adamantinomatous craniopharyngioma.
    Neuro Oncol. 2022 Dec 1:noac261. doi: 10.1093.
    >> Share

    November 2022
  299. GONZALEZ CASTRO LN, Liu I, Filbin M
    Erratum to: Characterizing the biology of primary brain tumors and their microenvironment via single-cell profiling methods.
    Neuro Oncol. 2022 Nov 29:noac257. doi: 10.1093.
    >> Share

  300. PRINS RM, Everson RG
    Commentary on "Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.".
    Neuro Oncol. 2022 Nov 29:noac256. doi: 10.1093.
    >> Share

  301. GERRITSEN JKW, Zwarthoed RH, Kilgallon JL, Nawabi NL, et al
    Impact of maximal extent of resection on postoperative deficits, patient functioning and survival within clinically important glioblastoma subgroups.
    Neuro Oncol. 2022 Nov 24:noac255. doi: 10.1093.
    >> Share

  302. LIN B, Ziebro J, Smithberger E, Skinner KR, et al
    Corrigendum to: EGFR, the Lazarus target for precision oncology in glioblastoma.
    Neuro Oncol. 2022 Nov 23:noac254. doi: 10.1093.
    >> Share

  303. DEAN JA, Tanguturi SK, Cagney D, Shin KY, et al
    Phase I study of a novel glioblastoma radiation therapy schedule exploiting cell-state plasticity.
    Neuro Oncol. 2022 Nov 19:noac253. doi: 10.1093.
    >> Share

  304. ZHANG IY, Liu S, Zhang L, Liang R, et al
    RAGE Ablation Attenuates Glioma Progression and Enhances Tumor Immune Responses by Suppressing Galectin-3 Expression.
    Neuro Oncol. 2022 Nov 17. pii: 6832182. doi: 10.1093.
    >> Share

  305. FORRY S, Hubbard L, Espey MG, Vikram B, et al
    The NCI Glioblastoma Therapeutics Network (GTN).
    Neuro Oncol. 2022 Nov 11. pii: 6822421. doi: 10.1093.
    >> Share

  306. GIRARDI F, Matz M, Stiller C, You H, et al
    Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3).
    Neuro Oncol. 2022 Nov 10. pii: 6819785. doi: 10.1093.
    >> Share


  307. Corrigendum to: Influence of county-level geographic/ancestral origin on glioma incidence and outcomes in US Hispanics.
    Neuro Oncol. 2022 Nov 8. pii: 6809298. doi: 10.1093.
    >> Share

  308. CHEN L, Xie X, Wang T, Xu L, et al
    ARL13B promotes angiogenesis and glioma growth by activating VEGFA-VEGFR2 signaling.
    Neuro Oncol. 2022 Nov 2. pii: 6794117. doi: 10.1093.
    >> Share

  309. SMITH K, Nakaji P, Thomas T, Pinnaduwage D, et al
    Safety and patterns of survivorship in recurrent GBM following resection and surgically targeted radiation therapy: Results from a prospective trial.
    Neuro Oncol. 2022;24.
    >> Share

  310. MCCRACKEN DJ, Schupper AJ, Lakomkin N, Malcolm J, et al
    Turning on the light for brain tumor surgery: A 5-aminolevulinic acid story.
    Neuro Oncol. 2022;24.
    >> Share

  311. ODIA Y, Gutierrez AN, Kotecha R
    Stereotactic targeted radiation therapy (STaRT) trials for brain neoplasms: A comprehensive review.
    Neuro Oncol. 2022;24.
    >> Share

  312. SCHUPPER AJ, Chanenchuk T, Racanelli A, Price G, et al
    Laser hyperthermia: Past, present, and future.
    Neuro Oncol. 2022;24.
    >> Share

  313. WU A, Wu JY, Lim M
    Updates in intraoperative strategies for enhancing intra-axial brain tumor control.
    Neuro Oncol. 2022;24.
    >> Share

  314. HADDAD AF, Aghi MK, Butowski N
    Novel intraoperative strategies for enhancing tumor control: Future directions.
    Neuro Oncol. 2022;24.
    >> Share

  315. HOOGENDIJK R, van der Lugt J, Hoving E, Kremer L, et al
    The fifth edition of the World Health Organization Classification of Tumors of the Central Nervous System: Implications for cancer registries.
    Neuro Oncol. 2022;24:1811-1814.
    >> Share

  316. GALLDIKS N, Langen KJ, Albert NL, Law I, et al
    Investigational PET tracers in neuro-oncology-What's on the horizon? A report of the PET/RANO group.
    Neuro Oncol. 2022;24:1815-1826.
    >> Share

  317. YEO KK, MacDonald SM
    CNS non-germinomatous germ cell tumor (NGGCT): Lessons from the recent past.
    Neuro Oncol. 2022;24:1962-1963.
    >> Share

  318. FONSECA A, Faure-Conter C, Murray MJ, Fangusaro J, et al
    Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials.
    Neuro Oncol. 2022;24:1950-1961.
    >> Share

    October 2022
  319. NAKATA S, Murai J, Okada M, Takahashi H, et al
    Epigenetic upregulation of Schlafen11 renders WNT- and SHH- activated medulloblastomas sensitive to cisplatin.
    Neuro Oncol. 2022 Oct 23. pii: 6770101. doi: 10.1093.
    >> Share

  320. ZHAO J, Yang S, Cui X, Wang Q, et al
    A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma.
    Neuro Oncol. 2022 Oct 22. pii: 6770036. doi: 10.1093.
    >> Share

  321. KOEKKOEK JAF, van der Meer PB, Pace A, Hertler C, et al
    Palliative care and end-of-life care in adults with malignant brain tumors.
    Neuro Oncol. 2022 Oct 22. pii: 6769915. doi: 10.1093.
    >> Share

  322. SHORT SC
    EV packing allows meningioma tracking in blood.
    Neuro Oncol. 2022 Oct 21. pii: 6765271. doi: 10.1093.
    >> Share

  323. RUDA R
    Optimize Treatment Approaches In Isocitrate Dehydrogenase (Idh) Mutant Gliomas: Open Issues.
    Neuro Oncol. 2022 Oct 17. pii: 6761819. doi: 10.1093.
    >> Share

  324. CHANG G, Xie GS, Ma L, Li P, et al
    USP36 promotes tumorigenesis and drug sensitivity of glioblastoma by deubiquitinating and stabilizing ALKBH5.
    Neuro Oncol. 2022 Oct 14. pii: 6761025. doi: 10.1093.
    >> Share

  325. GREEN K, Panagopoulou P, D'Arco F, O'Hare P, et al
    A Nationwide Evaluation of Bevacizumab-based Treatments in Paediatric Low-Grade Glioma in the UK: Safety. Efficacy, Visual Morbidity and Outcomes.
    Neuro Oncol. 2022 Oct 14. pii: 6761018. doi: 10.1093.
    >> Share

  326. AWADA H, Paris F, Pecqueur C
    Exploiting Radiation Immunostimulatory Effects To Improve Glioblastoma Outcome.
    Neuro Oncol. 2022 Oct 14. pii: 6761020. doi: 10.1093.
    >> Share

  327. CHOUDHURY A, Chen WC, Lucas CG, Bayley JC, et al
    Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features.
    Neuro Oncol. 2022 Oct 13. pii: 6760303. doi: 10.1093.
    >> Share

  328. MILLER JJ, Gonzalez Castro LN, McBrayer S, Weller M, et al
    Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.
    Neuro Oncol. 2022 Oct 12. pii: 6761148. doi: 10.1093.
    >> Share

  329. KOROVINA I, Vehlow A, Temme A, Cordes N, et al
    Targeting integrin alpha2 as potential strategy for radiochemosensitization of glioblastoma.
    Neuro Oncol. 2022 Oct 11. pii: 6758417. doi: 10.1093.
    >> Share

  330. SCHAKELAAR MY, Monnikhof M, Crnko S, Pijnappel E, et al
    Cellular Immunotherapy for Medulloblastoma.
    Neuro Oncol. 2022 Oct 11. pii: 6758415. doi: 10.1093.
    >> Share

  331. WOLLRING MM, Werner JM, Bauer EK, Tscherpel C, et al
    Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET.
    Neuro Oncol. 2022 Oct 10. pii: 6755441. doi: 10.1093.
    >> Share

  332. YANG R, Zhang G, Dong Z, Wang S, et al
    HOXA3 and KDM6A cooperate in transcriptional control of aerobic glycolysis and glioblastoma progression.
    Neuro Oncol. 2022 Oct 10. pii: 6755443. doi: 10.1093.
    >> Share

  333. GIRARDI F, Di Carlo V, Stiller C, Gatta G, et al
    Global survival trends for brain tumours, by histology: analysis of individual records for 67,776 children diagnosed in 61 countries during 2000-2014 (CONCORD-3).
    Neuro Oncol. 2022 Oct 10. pii: 6755369. doi: 10.1093.
    >> Share

  334. GONZALEZ CASTRO LN, Liu I, Filbin M
    Characterizing the biology of primary brain tumors and their microenvironment via single-cell profiling methods.
    Neuro Oncol. 2022 Oct 5. pii: 6748723. doi: 10.1093.
    >> Share

  335. OSTROM QT, Price M, Neff C, Cioffi G, et al
    CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019.
    Neuro Oncol. 2022;24.
    >> Share

  336. KUMTHEKAR P, Nagpal S
    Preclinical modeling in leptomeningeal disease: Starting at the foundation to tackle a difficult disease.
    Neuro Oncol. 2022;24:1687-1688.
    >> Share

  337. LUKAS RV
    Leptomeningeal metastases-What outcomes should we measure and how?
    Neuro Oncol. 2022;24:1736-1737.
    >> Share

  338. BOCKMAYR M, Harnisch K, Pohl LC, Schweizer L, et al
    Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease.
    Neuro Oncol. 2022;24:1689-1699.
    >> Share

  339. LAW V, Chen Z, Vena F, Smalley I, et al
    A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma.
    Neuro Oncol. 2022;24:1673-1686.
    >> Share

  340. LE RHUN E, Devos P, Winklhofer S, Lmalem H, et al
    Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort.
    Neuro Oncol. 2022;24:1726-1735.
    >> Share

    September 2022
  341. LIN B, Ziebro J, Smithberger E, Skinner KR, et al
    EGFR, the Lazarus target for precision oncology in glioblastoma.
    Neuro Oncol. 2022 Sep 19. pii: 6705404. doi: 10.1093.
    >> Share

  342. HOFFMAN LM, Jaimes C, Mankad K, Mirsky DM, et al
    Response assessment in pediatric craniopharyngioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.
    Neuro Oncol. 2022 Sep 17. pii: 6702540. doi: 10.1093.
    >> Share

  343. KASHANI E, Schnidrig D, Hashemi Gheinani A, Ninck MS, et al
    Integrated longitudinal analysis of adult grade 4 diffuse gliomas with long-term relapse interval revealed upregulation of TGF-beta signaling in recurrent tumors.
    Neuro Oncol. 2022 Sep 17. pii: 6702539. doi: 10.1093.
    >> Share

  344. OSTROM QT, Price M, Ryan K, Edelson J, et al
    CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018.
    Neuro Oncol. 2022;24.
    >> Share

  345. STEJEREAN-TODORAN I, Gimotty PA, Watters A, Brafford P, et al
    A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cells.
    Neuro Oncol. 2022 Sep 2. pii: 6687782. doi: 10.1093.
    >> Share

  346. INDELICATO DJ
    No question: Proton therapy is safe.
    Neuro Oncol. 2022;24:1582-1583.
    >> Share

    August 2022
  347. YU K, Kong K, Lozzi B, Luna-Figueroa E, et al
    In Vivo Functional Characterization of EGFR Variants Identifies Novel Drivers of Glioblastoma.
    Neuro Oncol. 2022 Aug 31. pii: 6679484. doi: 10.1093.
    >> Share

  348. BEDDOK A, Scher N, Alapetite C, Baussart B, et al
    Protontherapy for adult craniopharyngioma: experience of a single institution in 91 consecutive patients.
    Neuro Oncol. 2022 Aug 25. pii: 6674791. doi: 10.1093.
    >> Share

  349. OSTROM QT, Shoaf ML, Cioffi G, Waite K, et al
    National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.
    Neuro Oncol. 2022 Aug 22. pii: 6673397. doi: 10.1093.
    >> Share

  350. YOUNGBLOOD MW, Tran AN, Wang W, An S, et al
    Docetaxel Targets Aggressive Methylation Profiles and Serves as a Radiosensitizer in High-Risk Meningiomas.
    Neuro Oncol. 2022 Aug 17. pii: 6670614. doi: 10.1093.
    >> Share

  351. SHI DD, Youssef GC, Nassar AH, Lim-Fat MJ, et al
    Improved survival among females and association with lymphopenia in patients with newly diagnosed glioblastoma.
    Neuro Oncol. 2022 Aug 16. pii: 6668736. doi: 10.1093.
    >> Share

  352. VAN OPIJNEN MP, Tesileanu CMS, Dirven L, van der Meer PB, et al
    IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas.
    Neuro Oncol. 2022 Aug 16. pii: 6668487. doi: 10.1093.
    >> Share

  353. KARSCHNIA P, Young JS, Dono A, Hani L, et al
    Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group.
    Neuro Oncol. 2022 Aug 12. pii: 6664041. doi: 10.1093.
    >> Share

  354. SEYVE A, Dehais C, Chinot O, Djelad A, et al
    Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: a POLA network study.
    Neuro Oncol. 2022 Aug 12. pii: 6661438. doi: 10.1093.
    >> Share

  355. LUO X, Yang Y, Yin S, Li H, et al
    False-negative and false-positive outcomes of computer aided detection on brain metastasis: secondary analysis of a multicenter, multireader study.
    Neuro Oncol. 2022 Aug 9. pii: 6658946. doi: 10.1093.
    >> Share

  356. RUDA R, Capper D, Waldman AD, Pallud J, et al
    Eano-Euracan-Sno Guidelines on Circumscribed Astrocytic GLIOMAS, Glioneuronal and Neuronaltumors.
    Neuro Oncol. 2022 Aug 1. pii: 6652587. doi: 10.1093.
    >> Share

  357. BOELE FW, den Otter PWM, Reijneveld JC, de Witt Hamer PC, et al
    Long-term wellbeing and neurocognitive functioning of diffuse low-grade glioma patients and their caregivers: a longitudinal study spanning two decades.
    Neuro Oncol. 2022 Aug 1. pii: 6652588. doi: 10.1093.
    >> Share

  358. VARADHARAJAN S, Mack SC
    Leveraging epigenomic patterns to resolve the heterogeneity and origins of CNS germ cell tumors.
    Neuro Oncol. 2022;24:1259-1260.
    >> Share

  359. DESJARDINS A
    Improving survival in neuro-oncology is a struggle; we cannot allow ourselves to also struggle with issues of diversity.
    Neuro Oncol. 2022;24:1350-1351.
    >> Share

  360. YAO H, Xie W, Dai Y, Liu Y, et al
    TRIM65 determines the fate of a novel subtype of pituitary neuroendocrine tumors via ubiquitination and degradation of TPIT.
    Neuro Oncol. 2022;24:1286-1297.
    >> Share

  361. TAKAMI H, Elzawahry A, Mamatjan Y, Fukushima S, et al
    Transcriptome and methylome analysis of CNS germ cell tumor finds its cell-of-origin in embryogenesis and reveals shared similarities with testicular counterparts.
    Neuro Oncol. 2022;24:1246-1258.
    >> Share

  362. KOH KN, Wong RX, Lee DE, Han JW, et al
    Outcomes of intracranial germinoma-A retrospective multinational Asian study on effect of clinical presentation and differential treatment strategies.
    Neuro Oncol. 2022;24:1389-1399.
    >> Share

    July 2022
  363. HERTLER C, Seystahl K, Le Rhun E, Wirsching HG, et al
    Improved seizure control in patients with recurrent glioblastoma treated with bevacizumab.
    Neuro Oncol. 2022 Jul 30. pii: 6652283. doi: 10.1093.
    >> Share


  364. Erratum to: Environmental and sex-specific molecular signatures of glioma causation.
    Neuro Oncol. 2022 Jul 29. pii: 6651886. doi: 10.1093.
    >> Share

  365. CHEN AT, Xiao Y, Tang X, Baqri M, et al
    Cross-platform analysis reveals cellular and molecular landscape of glioblastoma invasion.
    Neuro Oncol. 2022 Jul 28. pii: 6651351. doi: 10.1093.
    >> Share

  366. SIGAUD R, Rosch L, Gatzweiler C, Benzel J, et al
    The first-in-class ERK inhibitor ulixertinib shows promising activity in MAPK-driven pediatric low-grade glioma models.
    Neuro Oncol. 2022 Jul 27. pii: 6650335. doi: 10.1093.
    >> Share

  367. DREXLER R, Schuller U, Eckhardt A, Filipski K, et al
    DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients.
    Neuro Oncol. 2022 Jul 22. pii: 6648783. doi: 10.1093.
    >> Share

  368. WALSH KM, Neff C, Bondy ML, Kruchko C, et al
    Influence of county-level geographic/ancestral origin on glioma incidence and outcomes in US Hispanics.
    Neuro Oncol. 2022 Jul 22. pii: 6648782. doi: 10.1093.
    >> Share

  369. KOSTI A, Chiou J, Guardia GDA, Lei X, et al
    ELF4 is a critical component of a miRNA-transcription factor network and is a bridge regulator of glioblastoma receptor signaling and lipid dynamics.
    Neuro Oncol. 2022 Jul 21. pii: 6648020. doi: 10.1093.
    >> Share

  370. LASSMAN AB, Pugh SL, Wang TJC, Aldape K, et al
    Depatuxizumab-mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial.
    Neuro Oncol. 2022 Jul 15. pii: 6645128. doi: 10.1093.
    >> Share

  371. BUEHLER M, Yi X, Ge W, Blattmann P, et al
    Quantitative proteomic landscapes of primary and recurrent glioblastoma reveal a protumorigeneic role for FBXO2-dependent glioma-microenvironment interactions.
    Neuro Oncol. 2022 Jul 8. pii: 6634186. doi: 10.1093.
    >> Share

  372. REYES-GONZALEZ J, Barajas-Olmos F, Garcia-Ortiz H, Magraner-Pardo L, et al
    Brain Radiotoxicity-Related 15CAcBRT Gene Expression Signature Predicts Survival Prognosis of Glioblastoma Patients.
    Neuro Oncol. 2022 Jul 8. pii: 6634161. doi: 10.1093.
    >> Share

  373. VAN DER VOORT SR, Incekara F, Wijnenga MMJ, Kapsas G, et al
    Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning.
    Neuro Oncol. 2022 Jul 5. pii: 6631283. doi: 10.1093.
    >> Share

  374. HUSE JT
    A Promising Preclinical Model For Tert Promoter Mutation In Glioblastoma.
    Neuro Oncol. 2022 Jul 3. pii: 6628220. doi: 10.1093.
    >> Share

  375. DONAHUE BR, MacDonald S
    Protons for pediatric ependymoma: Where are we now?
    Neuro Oncol. 2022;24:1203-1204.
    >> Share

  376. MILLWARD CP, Armstrong TS, Barrington H, Brodbelt AR, et al
    Opportunities and challenges for the development of "core outcome sets" in neuro-oncology.
    Neuro Oncol. 2022;24:1048-1055.
    >> Share

  377. HERRGOTT GA, Asmaro KP, Wells M, Sabedot TS, et al
    Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors.
    Neuro Oncol. 2022;24:1126-1139.
    >> Share

  378. PETERS S, Merta J, Schmidt L, Jazmati D, et al
    Evaluation of dose, volume, and outcome in children with localized, intracranial ependymoma treated with proton therapy within the prospective KiProReg Study.
    Neuro Oncol. 2022;24:1193-1202.
    >> Share

    June 2022
  379. PALMER JD, Prasad RN, Cioffi G, Kruchtko C, et al
    Exposure to Radon and Heavy Particulate Pollution and Incidence of Brain Tumors.
    Neuro Oncol. 2022 Jun 28. pii: 6618967. doi: 10.1093.
    >> Share

  380. AIZER AA, Lamba N, Ahluwalia MS, Aldape K, et al
    Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions.
    Neuro Oncol. 2022 Jun 28. pii: 6618874. doi: 10.1093.
    >> Share

  381. NOBRE L, Bouffet E
    BRAF inhibitors in BRAFV600E mutated pediatric high-grade gliomas: upfront or at recurrence?
    Neuro Oncol. 2022 Jun 24. pii: 6617660. doi: 10.1093.
    >> Share

  382. WEISHAUPT H, Cancer M, Rosen G, Holmberg KO, et al
    Novel cancer gene discovery using a forward genetic screen in RCAS-PDGFB-driven gliomas.
    Neuro Oncol. 2022 Jun 23. pii: 6615415. doi: 10.1093.
    >> Share

  383. CHEN X, Niu W, Fan X, Yang H, et al
    Oct4A palmitoylation modulates tumorigenicity and stemness in human glioblastoma cells.
    Neuro Oncol. 2022 Jun 21. pii: 6612239. doi: 10.1093.
    >> Share

  384. WANG Y, Wang K, Fu J, Zhang Y, et al
    FRK inhibits glioblastoma progression via phosphorylating YAP and inducing its ubiquitylation and degradation by Siah1.
    Neuro Oncol. 2022 Jun 20. pii: 6611687. doi: 10.1093.
    >> Share

  385. NATSUME A, Arakawa Y, Narita Y, Sugiyama K, et al
    The first-in-human phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas.
    Neuro Oncol. 2022 Jun 20. pii: 6611503. doi: 10.1093.
    >> Share

  386. LIU XP, Jin X, Ahmadian SS, Yang X, et al
    Clinical Significance and Molecular Annotation of Cellular Morphometric Subtypes in Lower Grade Gliomas discovered by Machine Learning.
    Neuro Oncol. 2022 Jun 18. pii: 6611075. doi: 10.1093.
    >> Share

  387. OSTROM QT, Lu D, Lu R, Baker MC, et al
    Prevalence of autoimmunity and atopy in US adults with glioblastoma and meningioma.
    Neuro Oncol. 2022 Jun 17. pii: 6609733. doi: 10.1093.
    >> Share

  388. SARAF A, Yock TI, Niemierko A, Oh KS, et al
    Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: a contemporary single-institution experience.
    Neuro Oncol. 2022 Jun 7. pii: 6603917. doi: 10.1093.
    >> Share

  389. LEE-CHANG C
    Understanding the relationship between gliomas and T cells: Paving the way for effective immunotherapy.
    Neuro Oncol. 2022 Jun 6. pii: 6602133. doi: 10.1093.
    >> Share

  390. ROGERS CL, Pugh SL, Vogelbaum MA, Perry A, et al
    Low-Risk Meningioma: Initial Outcomes from NRG Oncology/RTOG 0539.
    Neuro Oncol. 2022 Jun 3. pii: 6601387. doi: 10.1093.
    >> Share

  391. TAYLOR JW, Weyer-Jamora C, Hervey-Jumper S
    Molecularly determining cognition in glioma: New insights as the plot thickens.
    Neuro Oncol. 2022 Jun 3. pii: 6601533. doi: 10.1093.
    >> Share

  392. POON MTC, Brennan PM, Jin K, Sudlow CLM, et al
    Standardizing reporting of brain and central nervous system tumors in the United Kingdom.
    Neuro Oncol. 2022;24:1032-1033.
    >> Share

  393. MANGUM R, Parsons DW
    TRK inhibition for pediatric and adult central nervous system tumors: Early promise and future questions.
    Neuro Oncol. 2022;24:1008-1009.
    >> Share

  394. FAROUK SAIT S, Karajannis MA
    Chemotherapy plus focal radiation therapy for localized intracranial germinoma: How little is enough?
    Neuro Oncol. 2022;24:984-985.
    >> Share

  395. CAI F, Chen S, Yu X, Zhang J, et al
    Transcription factor GTF2B regulates AIP protein expression in growth hormone-secreting pituitary adenomas and influences tumor phenotypes.
    Neuro Oncol. 2022;24:925-935.
    >> Share

  396. BARTELS U, Onar-Thomas A, Patel SK, Shaw D, et al
    Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children's Oncology Group study.
    Neuro Oncol. 2022;24:974-983.
    >> Share

  397. PARK AK, Waheed A, Forst DA, Al-Samkari H, et al
    Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignancies.
    Neuro Oncol. 2022;24:964-973.
    >> Share

    May 2022

  398. Erratum to: Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma.
    Neuro Oncol. 2022 May 27. pii: 6594729. doi: 10.1093.
    >> Share

  399. NOBRE L, Hawkins C
    Liquid biopsy for pediatric brain tumor patients: is it prime time yet?
    Neuro Oncol. 2022 May 27. pii: 6593987. doi: 10.1093.
    >> Share

  400. VERPLOEGH ISC, Conidi A, Brouwer RWW, Balcioglu HE, et al
    Comparative single-cell RNA-sequencing profiling of BMP4-treated primary glioma cultures reveals therapeutic markers.
    Neuro Oncol. 2022 May 26. pii: 6593858. doi: 10.1093.
    >> Share

  401. DE LA FUENTE MI, Colman H, Rosenthal M, Van Tine BA, et al
    Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase 1b/2 trial.
    Neuro Oncol. 2022 May 25. pii: 6593129. doi: 10.1093.
    >> Share

  402. FRIEDRICH M, Hahn M, Michel J, Sankowski R, et al
    Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.
    Neuro Oncol. 2022 May 24. pii: 6591514. doi: 10.1093.
    >> Share

  403. GRIGUOLO G, Tosi A, Dieci MV, Fineberg S, et al
    A comprehensive profiling of the immune microenvironment of breast cancer brain metastases.
    Neuro Oncol. 2022 May 24. pii: 6591493. doi: 10.1093.
    >> Share

  404. MESSINGER D, Harris MK, Cummings JR, Thomas C, et al
    Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma.
    Neuro Oncol. 2022 May 23. pii: 6590903. doi: 10.1093.
    >> Share

  405. YEO KK, Alexandrescu S, Cotter JA, Vogelzang J, et al
    Multi-institutional study of the frequency, genomic landscape and outcome of IDH-mutant glioma in paediatrics.
    Neuro Oncol. 2022 May 23. pii: 6590765. doi: 10.1093.
    >> Share

  406. GIRARDI F, Coleman MP, Allemani C
    Reply to "Reporting pediatric brain tumors according to their behavior code can result in biased survival estimates-A European perspective to Girardi et al".
    Neuro Oncol. 2022 May 21. pii: 6590321. doi: 10.1093.
    >> Share

  407. HOOGENDIJK R, van der Lugt J, van Vuurden DG, Visser O, et al
    Reporting pediatric brain tumors according to their behavior code can result in biased survival estimates-A European perspective to Girardi et al.
    Neuro Oncol. 2022 May 21. pii: 6590318. doi: 10.1093.
    >> Share

  408. EDMONSTON DY, Wu S, Li Y, Khan RB, et al
    Limited Surgery and Conformal Photon Radiation Therapy for Pediatric Craniopharyngioma: Long-term Results from the RT1 Protocol.
    Neuro Oncol. 2022 May 12. pii: 6585053. doi: 10.1093.
    >> Share

  409. SAMPETREAN O, Saya H
    What can metabolites tell us about gliomas?
    Neuro Oncol. 2022 May 12. pii: 6584800. doi: 10.1093.
    >> Share

  410. BARTLETT A, Lane A, Chaney B, Escorza NY, et al
    Characteristics of Children
    Neuro Oncol. 2022 May 12. pii: 6585024. doi: 10.1093.
    >> Share

  411. RICKLEFS FL, Maire CL, Wollmann K, Duhrsen L, et al
    Diagnostic potential of extracellular vesicles in meningioma patients.
    Neuro Oncol. 2022 May 12. pii: 6585054. doi: 10.1093.
    >> Share

  412. REED-GUY L, Desai AS, Phillips RE, Croteau D, et al
    Risk of intracranial hemorrhage with direct oral anticoagulants versus low molecular weight heparin in glioblastoma: A retrospective cohort study.
    Neuro Oncol. 2022 May 12. pii: 6585055. doi: 10.1093.
    >> Share

  413. ROESLER R, de Farias CB, Brunetto AT, Gregianin L, et al
    Possible mechanisms and biomarkers of resistance to vismodegib in SHH medulloblastoma.
    Neuro Oncol. 2022 May 11. pii: 6584501. doi: 10.1093.
    >> Share


  414. Erratum to: path-03. Ferroptosis-related long non-coding rna signatures predict prognosis in patients with glioma.
    Neuro Oncol. 2022 May 9. pii: 6583332. doi: 10.1093.
    >> Share

  415. WINKLER F
    Understanding epilepsy in IDH-mutated gliomas: towards a targeted therapy.
    Neuro Oncol. 2022 May 9. pii: 6582767. doi: 10.1093.
    >> Share

  416. GALLDIKS N, Lohmann P, Langen KJ
    The role of 11C-methionine PET in patients with newly diagnosed WHO grade 2 or 3 gliomas.
    Neuro Oncol. 2022 May 5. pii: 6581471. doi: 10.1093.
    >> Share

  417. CASES-CUNILLERA S, van Loo KMJ, Pitsch J, Quatraccioni A, et al
    Heterogeneity and excitability of BRAFV600E-induced tumors is determined by Akt/mTOR-signaling state and Trp53-loss.
    Neuro Oncol. 2022;24:741-754.
    >> Share

  418. SATOMI K, Takami H, Fukushima S, Yamashita S, et al
    12p gain is predominantly observed in non-germinomatous germ cell tumors and identifies an unfavorable subgroup of central nervous system germ cell tumors.
    Neuro Oncol. 2022;24:834-846.
    >> Share

  419. LAZOW MA, Fuller C, DeWire M, Lane A, et al
    Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry.
    Neuro Oncol. 2022;24:821-833.
    >> Share

  420. RUDA R, Bruno F, Ius T, Silvani A, et al
    IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups.
    Neuro Oncol. 2022;24:809-820.
    >> Share

  421. FELIX M, Friedel D, Jayavelu AK, Filipski K, et al
    HIP1R and Vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.
    Neuro Oncol. 2022 May 3. pii: 6578556. doi: 10.1093.
    >> Share

  422. RICKLEFS FL, Drexler R, Wollmann K, Eckhardt A, et al
    DNA Methylation subclass Receptor Tyrosine Kinase II (RTK II) is predictive for seizure development in glioblastoma patients.
    Neuro Oncol. 2022 May 2. pii: 6577052. doi: 10.1093.
    >> Share

  423. LIM M, Weller M, Idbaih A, Steinbach J, et al
    Phase 3 Trial of Chemoradiotherapy With Temozolomide Plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma With Methylated MGMT Promoter.
    Neuro Oncol. 2022 May 2. pii: 6577049. doi: 10.1093.
    >> Share

    April 2022
  424. PERSSON ML, Douglas AM, Alvaro F, Faridi P, et al
    The intrinsic and microenvironmental features of diffuse midline glioma; implications for the development of effective immunotherapeutic treatment strategies.
    Neuro Oncol. 2022 Apr 27. pii: 6575144. doi: 10.1093.
    >> Share

  425. MERCHANT TE, Edmonston DY, Wu S, Li Y, et al
    Endocrine Outcomes after Limited Surgery and Conformal Photon Radiation Therapy for Pediatric Craniopharyngioma: Long-term Results from the RT1 Protocol.
    Neuro Oncol. 2022 Apr 27. pii: 6575137. doi: 10.1093.
    >> Share

  426. DING J, Li X, Khan S, Zhang C, et al
    EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a non-canonical regulatory axis between EGFR and wild-type p53 in glioblastoma.
    Neuro Oncol. 2022 Apr 26. pii: 6574563. doi: 10.1093.
    >> Share

  427. GUTIERREZ-VALENCIA E, Kalyvas A, Villafuerte CJ, Millar BA, et al
    Factors Correlating with Survival Following Adjuvant or Definitive Radiosurgery for Large Brain Metastases.
    Neuro Oncol. 2022 Apr 26. pii: 6574580. doi: 10.1093.
    >> Share

  428. JAIN B, Dee EC, Jain U, Aizer AA, et al
    Trends in location of death for individuals with primary brain tumors in the United States.
    Neuro Oncol. 2022 Apr 26. pii: 6574444. doi: 10.1093.
    >> Share

  429. SCHONROCK A, Heinzelmann E, Steffl B, Demirdizen E, et al
    MEOX2 homeobox gene promotes growth of malignant gliomas.
    Neuro Oncol. 2022 Apr 25. pii: 6573906. doi: 10.1093.
    >> Share

  430. MA R, Rei M, Woodhouse I, Ferris K, et al
    Decitabine increases neoantigen and cancer testis antigen expression to enhance T cell-mediated toxicity against glioblastoma.
    Neuro Oncol. 2022 Apr 25. pii: 6573935. doi: 10.1093.
    >> Share

  431. MINAMI N, Hong D, Stevers N, Barger CJ, et al
    Imaging biomarkers of TERT or GABPB1 silencing in TERT-positive glioblastoma.
    Neuro Oncol. 2022 Apr 23. pii: 6573305. doi: 10.1093.
    >> Share

  432. IORGULESCU JB, Sun C, Neff C, Cioffi G, et al
    Molecular Biomarker-Defined Brain Tumors: Epidemiology, Validity, and Completeness in the United States.
    Neuro Oncol. 2022 Apr 23. pii: 6573306. doi: 10.1093.
    >> Share

  433. CHUNG C, Brown PD, Wefel JS
    Lessons learned from proton vs photon radiation therapy for glioblastoma signal-finding trial.
    Neuro Oncol. 2022 Apr 23. pii: 6573235. doi: 10.1093.
    >> Share

  434. PUROW B
    ONC201 and ONC206: metabolically ClipPing the wings of diffuse midline glioma.
    Neuro Oncol. 2022 Apr 23. pii: 6573255. doi: 10.1093.
    >> Share

  435. OMURO A, Brandes AA, Carpentier AF, Idbaih A, et al
    Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial.
    Neuro Oncol. 2022 Apr 14. pii: 6568419. doi: 10.1093.
    >> Share

  436. COUTURIER CP, Nadaf J, Li Z, Baig S, et al
    Glioblastoma scRNAseq Shows Treatment-induced, Immune-dependent Rise In Mesenchymal Cancer Cells, and Structural Variants in Distal Neural Stem Cells.
    Neuro Oncol. 2022 Apr 13. pii: 6567757. doi: 10.1093.
    >> Share

  437. COOMANS M, Dirven L, Aaronson N, Baumert BG, et al
    Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period.
    Neuro Oncol. 2022 Apr 11. pii: 6566436. doi: 10.1093.
    >> Share

  438. GHOSH S
    Breaking the DLG shackles in glioblastoma.
    Neuro Oncol. 2022 Apr 11. pii: 6566243. doi: 10.1093.
    >> Share

  439. ROSENBERG T, Yeo KK, Mauguen A, Alexandrescu S, et al
    Upfront Molecular Targeted Therapy for the Treatment of BRAF-Mutant Pediatric High-Grade Glioma.
    Neuro Oncol. 2022 Apr 9. pii: 6566011. doi: 10.1093.
    >> Share

  440. ZHANG L, Nesvick CL, Day CA, Choi J, et al
    STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
    Neuro Oncol. 2022 Apr 9. pii: 6566009. doi: 10.1093.
    >> Share

  441. KANMOUNYE US, Karekezi C, Nyalundja AD, Awad AK, et al
    Adult brain tumors in Sub-Saharan Africa: A scoping review.
    Neuro Oncol. 2022 Apr 9. pii: 6566010. doi: 10.1093.
    >> Share

  442. ZHANG Y, Lucas CG, Young JS, Morshed RA, et al
    Prospective genomically-guided identification of 'early/evolving' and 'undersampled' IDH-wildtype glioblastoma leads to improved clinical outcomes.
    Neuro Oncol. 2022 Apr 8. pii: 6565639. doi: 10.1093.
    >> Share

  443. BIEGEL JA
    Meeting the high expectations for liquid biopsy assays for pediatric brain tumors: progress and challenges.
    Neuro Oncol. 2022 Apr 5. pii: 6563880. doi: 10.1093.
    >> Share

  444. ELLINGSON BM, Gerstner ER, Lassman AB, Chung C, et al
    Hypothetical Generalized Framework for a New Imaging Endpoint of Therapeutic Activity in Early Phase Clinical Trials in Brain Tumors.
    Neuro Oncol. 2022 Apr 5. pii: 6563738. doi: 10.1093.
    >> Share

  445. TESILEANU CMS, Gorlia T, Golfinopoulos V, French PJ, et al
    MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas.
    Neuro Oncol. 2022;24:665-667.
    >> Share

  446. FRAPPAZ D, Dhall G, Murray MJ, Goldman S, et al
    EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults.
    Neuro Oncol. 2022;24:516-527.
    >> Share

  447. NAKAMURA H, Takami H, Yanagisawa T, Kumabe T, et al
    The Japan Society for Neuro-Oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors.
    Neuro Oncol. 2022;24:503-515.
    >> Share

  448. WU Z, Abdullaev Z, Pratt D, Chung HJ, et al
    Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics.
    Neuro Oncol. 2022;24:571-581.
    >> Share

    March 2022
  449. SARAN F, Eisenstat DD
    The relapse doesn't fall far from the radiotherapy field: Lessons to be learned for the future of radiotherapy in medulloblastoma from the relapse patterns of SJMB03.
    Neuro Oncol. 2022 Mar 24. pii: 6553345. doi: 10.1093.
    >> Share

  450. PIOTROWSKI AF, Jackson S
    Identifying risk factors for recurrence/relapse in NF1 optic pathway gliomas: Moving forward by looking back.
    Neuro Oncol. 2022 Mar 23. pii: 6553267. doi: 10.1093.
    >> Share

  451. CORDELL EC, Alghamri MS, Castro MG, Gutmann DH, et al
    T lymphocytes as dynamic regulators of glioma pathobiology.
    Neuro Oncol. 2022 Mar 23. pii: 6553145. doi: 10.1093.
    >> Share

  452. OSUKA S
    Targeting adaptive radioresistance in Glioblastoma.
    Neuro Oncol. 2022 Mar 22. pii: 6552309. doi: 10.1093.
    >> Share

  453. BLOBNER J, Tonn JC
    Resection of glioma - Feeding the beast?
    Neuro Oncol. 2022 Mar 22. pii: 6552311. doi: 10.1093.
    >> Share

  454. AZAD TD, Bettegowda C
    Longitudinal monitoring of diffuse midline glioma using liquid biopsy.
    Neuro Oncol. 2022 Mar 22. pii: 6552310. doi: 10.1093.
    >> Share

  455. LE RHUN E, Oppong FB, Vanlancker M, Stupp R, et al
    Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.
    Neuro Oncol. 2022 Mar 21. pii: 6551573. doi: 10.1093.
    >> Share

  456. ZHAN Q, Yi K, Cui X, Li X, et al
    Blood exosomes-based targeted delivery of cPLA2 siRNA and metformin to modulate glioblastoma energy metabolism for tailoring personalized therapy.
    Neuro Oncol. 2022 Mar 21. pii: 6551550. doi: 10.1093.
    >> Share

  457. QIN N, Paisana E, Langini M, Picard D, et al
    Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis.
    Neuro Oncol. 2022 Mar 21. pii: 6551011. doi: 10.1093.
    >> Share

  458. FANGUSARO JR, Onar-Thomas A, Poussaint TY, Wu S, et al
    Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study.
    Neuro Oncol. 2022 Mar 21. pii: 6551018. doi: 10.1093.
    >> Share

  459. FERDOSI SR, Taylor B, Lee M, Tang N, et al
    PTEN loss drives resistance to the neddylation inhibitor MLN4924 in glioblastoma and can be overcome with TOP2A inhibitors.
    Neuro Oncol. 2022 Mar 19. pii: 6550856. doi: 10.1093.
    >> Share

  460. BOUFFET E, Lafay-Cousin L
    Infant brain tumor trials: Beyond feasibility.
    Neuro Oncol. 2022 Mar 14. pii: 6548388. doi: 10.1093.
    >> Share

  461. ZHOU Y, Meng X, He W, Li XY, et al
    USF1/CD90 signaling in maintaining glioblastoma stem cells and tumor-associated macrophages adhesion.
    Neuro Oncol. 2022 Mar 14. pii: 6548387. doi: 10.1093.
    >> Share

  462. MOHAMED E, Kumar A, Zhang Y, Wang AS, et al
    PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications.
    Neuro Oncol. 2022 Mar 14. pii: 6548389. doi: 10.1093.
    >> Share

  463. FOREMAN NK
    Outcomes after first relapse of children with intracranial ependymoma treated on the second l'Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) protocol.
    Neuro Oncol. 2022;24:480-481.
    >> Share

  464. MILLER JJ, Wang N
    Body imaging for newly diagnosed CNS lymphoma: Evaluating the utility of the evaluation.
    Neuro Oncol. 2022;24:492-493.
    >> Share

  465. MASSIMINO M, Barretta F, Modena P, Johann P, et al
    Treatment and outcome of intracranial ependymoma after first relapse in the 2nd AIEOP protocol.
    Neuro Oncol. 2022;24:467-479.
    >> Share

  466. BURGENSKE DM, Talele S, Pokorny JL, Mladek AC, et al
    Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.
    Neuro Oncol. 2022;24:384-395.
    >> Share

  467. MILLER JJ, Cahill DP, Arrillaga-Romany I
    Enhancing demethylation-induced differentiation in IDH-mutant glioma.
    Neuro Oncol. 2022 Mar 3. pii: 6542042. doi: 10.1093.
    >> Share

  468. MLADEK AC, Yan H, Tian S, Decker PA, et al
    RBBP4-p300 Axis Modulates Expression of Genes Essential for Cell Survival and is a Potential Target for Therapy in Glioblastoma.
    Neuro Oncol. 2022 Mar 1. pii: 6540482. doi: 10.1093.
    >> Share

    February 2022
  469. BADODI S, Pomella N, Lim YM, Brandner S, et al
    Combination of BMI1 and MAPK/ERK inhibitors is effective in medulloblastoma.
    Neuro Oncol. 2022 Feb 25. pii: 6537125. doi: 10.1093.
    >> Share

  470. PAPUSHA L, Zaytseva M, Panferova A, Druy A, et al
    Two clinically distinct cases of infant hemispheric glioma carrying ZCCHC8:ROS1 fusion and responding to entrectinib.
    Neuro Oncol. 2022 Feb 23. pii: 6535118. doi: 10.1093.
    >> Share

  471. FERRARESE R, Carro MS
    Neural networks help zebrafish to step up as a model for efficient drug screening in glioblastoma.
    Neuro Oncol. 2022 Feb 19. pii: 6532496. doi: 10.1093.
    >> Share

  472. NINATTI G, Sollini M, Bono B, Gozzi N, et al
    Preoperative [11C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas.
    Neuro Oncol. 2022 Feb 16. pii: 6529477. doi: 10.1093.
    >> Share

  473. UPADHYAY R, Liao K, Grosshans DR, McGovern SL, et al
    Quantifying the risk and dosimetric variables of symptomatic brainstem injury after proton beam radiation in pediatric brain tumors.
    Neuro Oncol. 2022 Feb 14. pii: 6528473. doi: 10.1093.
    >> Share

  474. PRZYSTAL JM, Cosentino CC, Yadavilli S, Zhang J, et al
    Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas.
    Neuro Oncol. 2022 Feb 14. pii: 6528446. doi: 10.1093.
    >> Share

  475. BJORKBLOM B, Wibom C, Eriksson M, Bergenheim AT, et al
    Distinct metabolic hallmarks of WHO classified adult glioma subtypes.
    Neuro Oncol. 2022 Feb 14. pii: 6528465. doi: 10.1093.
    >> Share

  476. LIU T, Zhu C, Chen X, Guan G, et al
    Ferroptosis, as the most enriched programmed cell death process in glioma, induces immunosuppression and immunotherapy resistance.
    Neuro Oncol. 2022 Feb 11. pii: 6527229. doi: 10.1093.
    >> Share

  477. MILLER AM, Szalontay L, Bouvier N, Hill K, et al
    Next-generation Sequencing of Cerebrospinal Fluid for Clinical Molecular Diagnostics in Pediatric, Adolescent and Young Adult (AYA) Brain Tumor Patients.
    Neuro Oncol. 2022 Feb 11. pii: 6527231. doi: 10.1093.
    >> Share

  478. VAN KESSEL E, Berendsen S, Baumfalk AE, Venugopal H, et al
    Tumor-related molecular determinants of neurocognitive deficits in patients with diffuse glioma.
    Neuro Oncol. 2022 Feb 11. pii: 6527233. doi: 10.1093.
    >> Share

  479. LAZOW MA, Nievelstein MT, Lane A, Bandopadhayhay P, et al
    Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry.
    Neuro Oncol. 2022 Feb 11. pii: 6527234. doi: 10.1093.
    >> Share

  480. REBCHUK AD, Chaharyn BM, Alam A, Hounjet CD, et al
    The Impact of Brain Invasion Criteria on the Incidence and Distribution of WHO Grade 1, 2 and 3 Meningiomas.
    Neuro Oncol. 2022 Feb 9. pii: 6525422. doi: 10.1093.
    >> Share

  481. JO J, van den Bent MJ, Nabors B, Wen PY, et al
    Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas.
    Neuro Oncol. 2022 Feb 8. pii: 6524653. doi: 10.1093.
    >> Share

  482. CANTOR E, Wierzbicki K, Tarapore RS, Ravi K, et al
    Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma.
    Neuro Oncol. 2022 Feb 6. pii: 6523277. doi: 10.1093.
    >> Share

    January 2022
  483. YIN S, Luo X, Yang Y, Shao Y, et al
    Development and validation of a deep-learning model for detecting brain metastases on 3D post-contrast MRI: a multi-center multi-reader evaluation study.
    Neuro Oncol. 2022 Jan 31. pii: 6518101. doi: 10.1093.
    >> Share

  484. ALVAREZ-BRECKENRIDGE CA, Cahill DP, Brastianos PK
    Trabectedin for recurrent WHO grade 2 or 3 meningiomas-paving the road for new opportunities.
    Neuro Oncol. 2022 Jan 31. pii: 6518099. doi: 10.1093.
    >> Share

  485. READ RD
    Repurposing the drug verteporfin as anti-neoplastic therapy for glioblastoma.
    Neuro Oncol. 2022 Jan 31. pii: 6518098. doi: 10.1093.
    >> Share

  486. BROWN CE, Rodriguez A, Palmer J, Ostberg JR, et al
    Off-the-shelf, Steroid Resistant, IL13Ralpha2-Specific CAR T Cells for Treatment of Glioblastoma.
    Neuro Oncol. 2022 Jan 31. pii: 6518100. doi: 10.1093.
    >> Share

  487. LOWE SR, Wang CP, Brisco A, Whiting J, et al
    Surgical and Anatomic Factors Predict Development of Leptomeningeal Disease in Patients with Melanoma Brain Metastases.
    Neuro Oncol. 2022 Jan 29. pii: 6517353. doi: 10.1093.
    >> Share

  488. TAGLANG C, Batsios G, Mukherjee J, Tran M, et al
    Deuterium magnetic resonance spectroscopy enables non-invasive metabolic imaging of tumor burden and response to therapy in low-grade gliomas.
    Neuro Oncol. 2022 Jan 29. pii: 6517050. doi: 10.1093.
    >> Share

  489. GERSTNER ER
    Volumetric Measurements in Low Grade Glioma: Are we there yet?
    Neuro Oncol. 2022 Jan 28. pii: 6516793. doi: 10.1093.
    >> Share

  490. KOEKKOEK JAF, van der Meer PB, Taphoorn MJB, Dirven L, et al
    Letter regarding "SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors".
    Neuro Oncol. 2022 Jan 25. pii: 6515357. doi: 10.1093.
    >> Share

  491. PICCA A, Desjardins C, Bihan K, Weiss N, et al
    Progressive multifocal leukoencephalopathy after first-line radiotherapy and temozolomide for glioblastoma.
    Neuro Oncol. 2022 Jan 17. pii: 6509380. doi: 10.1093.
    >> Share

  492. RAHMAN R, Huang RY
    Deep learning approaches to non-invasively assess molecular features of gliomas.
    Neuro Oncol. 2022 Jan 13. pii: 6507359. doi: 10.1093.
    >> Share

  493. VOGELIUS IR, Bentzen SM
    Proton vs photon radiation therapy for glioblastoma: Maximizing information from trial.
    Neuro Oncol. 2022 Jan 13. pii: 6506534. doi: 10.1093.
    >> Share

  494. BECKER KN, Eisenmann KM
    New Targets in the Glioblastoma Tumor Microtube Multiverse: Emerging Roles for the TGF-beta/TSP1 Signaling Axis.
    Neuro Oncol. 2022 Jan 10. pii: 6502470. doi: 10.1093.
    >> Share

  495. TRAN AN
    Targeting glutamine addiction in meningioma.
    Neuro Oncol. 2022 Jan 10. pii: 6502476. doi: 10.1093.
    >> Share

  496. ESPINOZA FI, Walker PR
    Untangling macrophage/microglia complexity in glioblastoma subtypes to elucidate the impact of CSF1R inhibition.
    Neuro Oncol. 2022 Jan 10. pii: 6502489. doi: 10.1093.
    >> Share

  497. VOGELBAUM MA
    Balancing Maximal Resection and Functional Preservation in Surgery for Low Grade Glioma.
    Neuro Oncol. 2022 Jan 10. pii: 6502479. doi: 10.1093.
    >> Share

  498. KOTCH C, Avery R, Getz KD, Bouffet E, et al
    Risk Factors for Treatment Refractory and Relapsed Optic Pathway Glioma in Children with Neurofibromatosis Type 1.
    Neuro Oncol. 2022 Jan 9. pii: 6501465. doi: 10.1093.
    >> Share

  499. MAEGAWA S, Gopalakrishnan V
    PLK inhibitors come of age in pediatric brain tumors.
    Neuro Oncol. 2022 Jan 7. pii: 6499977. doi: 10.1093.
    >> Share

  500. SOFFIETTI R, Bettegowda C, Mellinghoff IK, Warren KE, et al
    Liquid biopsy in gliomas: a RANO review and proposals for clinical applications.
    Neuro Oncol. 2022 Jan 6. pii: 6499389. doi: 10.1093.
    >> Share

  501. MORTAZAVI A, Fayed I, Bachani M, Dowdy T, et al
    IDH Mutated Gliomas Promote Epileptogenesis through D-2-Hydroxyglutarate Dependent mTOR Hyperactivation.
    Neuro Oncol. 2022 Jan 5. pii: 6498134. doi: 10.1093.
    >> Share

  502. FURLAN JC, Wilson JR, Massicotte EM, Sahgal A, et al
    Recent advances and new discoveries in the pipeline of the treatment of primary spinal tumors and spinal metastases: a scoping review of registered clinical studies from 2000 to 2020.
    Neuro Oncol. 2022;24:1-13.
    >> Share

  503. JUHNKE BO, Gessi M, Gerber NU, Friedrich C, et al
    Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT trial.
    Neuro Oncol. 2022;24:127-137.
    >> Share

  504. LAMBA N, Catalano PJ, Bi WL, Wen PY, et al
    Predictors of long-term survival among patients with brain metastases.
    Neuro Oncol. 2022 Jan 4. pii: 6497420. doi: 10.1093.
    >> Share

  505. KUNDU S, Nandhu MS, Longo SL, Longo JA, et al
    The scaffolding protein DLG5 promotes glioblastoma growth by controlling Sonic Hedgehog signaling in tumor stem cells.
    Neuro Oncol. 2022 Jan 4. pii: 6497518. doi: 10.1093.
    >> Share

  506. PAGES M, Rotem D, Gydush G, Reed S, et al
    Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine.
    Neuro Oncol. 2022 Jan 4. pii: 6497435. doi: 10.1093.
    >> Share

    December 2021
  507. DE BILLY E, Pellegrino M, Orlando D, Pericoli G, et al
    Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant.
    Neuro Oncol. 2021 Dec 29. pii: 6489024. doi: 10.1093.
    >> Share

  508. KNUDSEN AM, Halle B, Cedile O, Burton M, et al
    Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors.
    Neuro Oncol. 2021 Dec 29. pii: 6489042. doi: 10.1093.
    >> Share

  509. HU C, Wang K, Damon C, Fu Y, et al
    ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma.
    Neuro Oncol. 2021 Dec 24. pii: 6482823. doi: 10.1093.
    >> Share

  510. MEISSNER AK, Gutsche R, Galldiks N, Kocher M, et al
    Radiomics for the non-invasive prediction of the BRAF mutation status in patients with melanoma brain metastases.
    Neuro Oncol. 2021 Dec 22. pii: 6478897. doi: 10.1093.
    >> Share

  511. LEARY SES, Lindsay K, Geyer JR, Mehmet K, et al
    Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026).
    Neuro Oncol. 2021 Dec 22. pii: 6478443. doi: 10.1093.
    >> Share

  512. DESHPANDE K, Martirosian V, Nakamura BN, Iyer M, et al
    Neuronal exposure induces neurotransmitter signaling and synaptic mediators in tumors early in brain metastasis.
    Neuro Oncol. 2021 Dec 21. pii: 6473228. doi: 10.1093.
    >> Share

  513. YABO YA, Niclou SP, Golebiewska A
    Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma.
    Neuro Oncol. 2021 Dec 21. pii: 6472977. doi: 10.1093.
    >> Share

  514. GU J, Mu N, Jia B, Guo Q, et al
    Targeting radiation-tolerant persister cells as a strategy for inhibiting radioresistance and recurrence in glioblastoma.
    Neuro Oncol. 2021 Dec 14. pii: 6461092. doi: 10.1093.
    >> Share

  515. LUCAS JT, Tinkle CL, Huang J, Onar-Thomas A, et al
    Revised clinical and molecular risk strata define the incidence and pattern of failure in Medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study.
    Neuro Oncol. 2021 Dec 11. pii: 6459719. doi: 10.1093.
    >> Share

  516. LIM-FAT MJ, Youssef GC, Touat M, Iorgulescu JB, et al
    Clinical utility of targeted next generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making.
    Neuro Oncol. 2021 Dec 8. pii: 6456497. doi: 10.1093.
    >> Share

  517. GARZIA L
    Faraway, so close: intratumoral heterogeneity of medulloblastoma subgroups.
    Neuro Oncol. 2021 Dec 4. pii: 6449209. doi: 10.1093.
    >> Share

  518. HAGIWARA A, Oughourlian TC, Cho NS, Schlossman J, et al
    Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.
    Neuro Oncol. 2021 Dec 2. pii: 6448328. doi: 10.1093.
    >> Share

  519. GUPTA T, Manjali JJ, Purandare N, Bagal B, et al
    Bone marrow biopsy in PCNSL: Relevant or redundant?
    Neuro Oncol. 2021;23:2117-2118.
    >> Share

  520. MARGOLD M, Schlegel U
    Reply to letter to the editor by Gupta et al: Bone marrow biopsy in patients with PCNSL: relevant or redundant?
    Neuro Oncol. 2021;23:2119.
    >> Share

  521. MOUDGIL-JOSHI J, Kaliaperumal C
    Letter regarding Louis et al: The 2021 WHO Classification of Tumors of the Central Nervous System: A summary.
    Neuro Oncol. 2021;23:2120-2121.
    >> Share

  522. ECKEL-PASSOW JE, Kitange GJ, Decker PA, Kosel ML, et al
    Experimental design of preclinical experiments: number of PDX lines vs subsampling within PDX lines.
    Neuro Oncol. 2021;23:2066-2075.
    >> Share

  523. MARNER L, Lundemann M, Sehested A, Nysom K, et al
    Diagnostic accuracy and clinical impact of [18F]FET PET in childhood CNS tumors.
    Neuro Oncol. 2021;23:2107-2116.
    >> Share

    November 2021
  524. CHAREST A
    Optimizing an effective combination of the new microtubule targeting agent Lisavanbulin with standard of care therapy for glioblastoma in patient-derived xenograft pre-clinical models.
    Neuro Oncol. 2021 Nov 27. pii: 6444804. doi: 10.1093.
    >> Share

  525. TAYLOR JW
    Treat the VTE and worry less about the hemorrhage: A sigh of relief or is the jury still out for therapeutic anticoagulation in high grade glioma?
    Neuro Oncol. 2021 Nov 27. pii: 6444703. doi: 10.1093.
    >> Share

  526. LEMAITRE AL, Herbet G, Ng S, Moritz-Gasser S, et al
    Cognitive preservation following awake mapping-based neurosurgery for low-grade gliomas: a longitudinal, within-patient design study.
    Neuro Oncol. 2021 Nov 26. pii: 6444171. doi: 10.1093.
    >> Share

  527. ABDULLAH KG, Bird CE, Buehler JD, Gattie LC, et al
    Establishment of patient-derived organoid models of lower grade glioma.
    Neuro Oncol. 2021 Nov 26. pii: 6444299. doi: 10.1093.
    >> Share

  528. CHIOCCA EA, Gelb AB, Chen CC, Rao G, et al
    Combined immunotherapy with controlled Interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: an open-label, multi-institutional phase 1 trial.
    Neuro Oncol. 2021 Nov 26. pii: 6444298. doi: 10.1093.
    >> Share

  529. DA COSTA ROSA M, Yamashita AS, Riggins GJ
    Evaluation of a DNA demethylating agent in combination with all-trans retinoic acid for IDH1-mutant gliomas.
    Neuro Oncol. 2021 Nov 26. pii: 6440681. doi: 10.1093.
    >> Share

  530. DE JOODE K, Taal W, Snijders TJ, Hanse M, et al
    Patients with primary brain tumors and COVID-19: A report from the Dutch Oncology COVID-19 Consortium.
    Neuro Oncol. 2021 Nov 24. pii: 6437945. doi: 10.1093.
    >> Share

  531. KIELISZEK AM, Aghaei N, Bassey-Archibong B, Singh SK, et al
    Low and steady wins the race: for melanoma-brain metastases, is prevention better than a cure?
    Neuro Oncol. 2021 Nov 24. pii: 6438512. doi: 10.1093.
    >> Share

  532. WU J
    Targeting nicotinamide adenosine dinucleotide (NAD) in diffuse gliomas.
    Neuro Oncol. 2021 Nov 22. pii: 6433381. doi: 10.1093.
    >> Share

  533. ALMSTEDT E, Rosen E, Gloger M, Stockgard R, et al
    Real-time evaluation of glioblastoma growth in patient-specific zebrafish xenografts.
    Neuro Oncol. 2021 Nov 19. pii: 6432157. doi: 10.1093.
    >> Share

  534. NASSIRI F, Wang JZ, Au K, Barnholtz-Sloan J, et al
    Consensus core clinical data elements for meningiomas.
    Neuro Oncol. 2021 Nov 17. pii: 6430437. doi: 10.1093.
    >> Share

  535. BALIGA S, Gallotto S, Bajaj B, Lewy J, et al
    Decade Long Disease, Secondary Malignancy, and Brainstem Injury Outcomes in Pediatric and Young Adult Medulloblastoma Patients Treated with Proton Radiotherapy.
    Neuro Oncol. 2021 Nov 12. pii: 6425899. doi: 10.1093.
    >> Share

  536. KACHURI L, Walsh KM
    Long telomeres in need of a SNP: Germline contributions of telomere maintenance to glioma.
    Neuro Oncol. 2021 Nov 10. pii: 6425113. doi: 10.1093.
    >> Share

  537. ELLINGSON BM, Kim GHJ, Brown M, Lee J, et al
    Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of Ivosidenib.
    Neuro Oncol. 2021 Nov 9. pii: 6424025. doi: 10.1093.
    >> Share

  538. ARAKAKI AKS, Szulzewsky F, Gilbert MR, Gujral TS, et al
    Utilizing preclinical models to develop targeted therapies for rare central nervous system cancers.
    Neuro Oncol. 2021;23.
    >> Share

  539. PRATT D, Sahm F, Aldape K
    DNA methylation profiling as a model for discovery and precision diagnostics in neuro-oncology.
    Neuro Oncol. 2021;23.
    >> Share

  540. ARMSTRONG TS, Gilbert MR
    Clinical trial challenges, design considerations, and outcome measures in rare CNS tumors.
    Neuro Oncol. 2021;23.
    >> Share

  541. PENAS-PRADO M
    Rare central nervous system tumors: the path to progress.
    Neuro Oncol. 2021;23.
    >> Share

  542. ASA SL, Mete O
    Single-cell transcriptome and genome analysis: A much-needed tool for pituitary neuroendocrine tumor studies.
    Neuro Oncol. 2021;23:1803-1804.
    >> Share

  543. CUI Y, Li C, Jiang Z, Zhang S, et al
    Single-cell transcriptome and genome analyses of pituitary neuroendocrine tumors.
    Neuro Oncol. 2021;23:1859-1871.
    >> Share

    October 2021
  544. MOLINARO AM
    External Controls to Improve on Glioblastoma Clinical Trials.
    Neuro Oncol. 2021 Oct 29. pii: 6414401. doi: 10.1093.
    >> Share

  545. ANDREWS LJ, Thornton ZA, Saincher SS, Yao IY, et al
    Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review.
    Neuro Oncol. 2021 Oct 28. pii: 6413773. doi: 10.1093.
    >> Share

  546. SCHWARTZBAUM J, Harris R
    Age at diagnosis and sex interact to modify primary malignant glioma incidence and survival.
    Neuro Oncol. 2021 Oct 25. pii: 6409990. doi: 10.1093.
    >> Share

  547. VACHHA BA, Huang RY
    BOLD Asynchrony: An imaging biomarker of tumor burden in IDH-mutated gliomas.
    Neuro Oncol. 2021 Oct 25. pii: 6409977. doi: 10.1093.
    >> Share

  548. PREUSSER M, Silvani A, Le Rhun E, Soffietti R, et al
    Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC Brain Tumor Group (EORTC-1320-BTG).
    Neuro Oncol. 2021 Oct 21. pii: 6406919. doi: 10.1093.
    >> Share

  549. BARRETTE AM, Ronk H, Joshi T, Mussa Z, et al
    Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor Verteporfin in preclinical glioblastoma models.
    Neuro Oncol. 2021 Oct 17. pii: 6398692. doi: 10.1093.
    >> Share

  550. CLUCERU J, Interian Y, Phillips JJ, Molinaro AM, et al
    Improving the noninvasive classification of glioma genetic subtype with deep learning and diffusion-weighted imaging.
    Neuro Oncol. 2021 Oct 15. pii: 6398212. doi: 10.1093.
    >> Share

  551. PANT A, Lim M
    Checkpoint blockade in recurrent meningiomas: Lessons for future management.
    Neuro Oncol. 2021 Oct 9. pii: 6385431. doi: 10.1093.
    >> Share

  552. HOOGSTRATE Y, Ghisai SA, de Wit M, de Heer I, et al
    The EGFRvIII transcriptome in glioblastoma, a meta-omics analysis.
    Neuro Oncol. 2021 Oct 5. pii: 6381406. doi: 10.1093.
    >> Share

  553. OSTROM QT, Cioffi G, Waite K, Kruchko C, et al
    CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018.
    Neuro Oncol. 2021;23.
    >> Share

  554. STROWD RE
    Etched in Code: Revisiting glioma risk factors through the exome.
    Neuro Oncol. 2021 Oct 4. pii: 6380799. doi: 10.1093.
    >> Share

  555. FRIEDMAN GK, Dhall G
    Potential Role of Carbon Ion Radiotherapy in Chromothripsis-induced Medulloblastoma and Other Malignancies.
    Neuro Oncol. 2021 Oct 4. pii: 6380754. doi: 10.1093.
    >> Share

  556. WU J, Gupta R, Barreto J, Doo P, et al
    Tumor DNA requirements for accurate epigenetic-based classification of CNS neoplasia.
    Neuro Oncol. 2021;23:1798-1800.
    >> Share

  557. PERTZ M, Schlegel U
    Tracking the neurobiology of cognitive dysfunction in primary CNS lymphoma?
    Neuro Oncol. 2021;23:1623-1624.
    >> Share

  558. MILDE T, Rodriguez FJ, Barnholtz-Sloan JS, Patil N, et al
    Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas.
    Neuro Oncol. 2021;23:1634-1646.
    >> Share

  559. GENG H, Tsang M, Subbaraj L, Cleveland J, et al
    Tumor metabolism and neurocognition in CNS lymphoma.
    Neuro Oncol. 2021;23:1668-1679.
    >> Share

    September 2021
  560. DEL BENE M, Osti D, Faletti S, Beznousenko GV, et al
    Extracellular vesicles: the key for precision medicine in glioblastoma.
    Neuro Oncol. 2021 Sep 28. pii: 6377304. doi: 10.1093.
    >> Share

  561. RAO R, Han R, Ogurek S, Xue C, et al
    Glioblastoma Genetic Drivers Dictate the Function of Tumor-Associated Macrophages/Microglia and Responses to CSF1R Inhibition.
    Neuro Oncol. 2021 Sep 25. pii: 6375369. doi: 10.1093.
    >> Share

  562. PENG J, Kim DD, Patel JB, Zeng X, et al
    Corrigendum to: Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors.
    Neuro Oncol. 2021 Sep 22. pii: 6374130. doi: 10.1093.
    >> Share

  563. JOSEPH JV, Magaut CR, Storevik S, Geraldo LH, et al
    TGF- promotes microtube formation in glioblastoma through Thrombospondin 1.
    Neuro Oncol. 2021 Sep 20. pii: 6372853. doi: 10.1093.
    >> Share

  564. LUCAS CG, Mueller S, Reddy A, Taylor JW, et al
    Diffuse hemispheric glioma, H3 G34-mutant: Genomic landscape of a new tumor entity and prospects for targeted therapy.
    Neuro Oncol. 2021 Sep 14. pii: 6370137. doi: 10.1093.
    >> Share

  565. WANG W, He H, Marin-Ramos NI, Zeng S, et al
    Corrigendum to: Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer.
    Neuro Oncol. 2021 Sep 14. pii: 6370123. doi: 10.1093.
    >> Share

  566. BORNHORST M
    New insights into low grade glioma tumor microenvironment for improved patient management.
    Neuro Oncol. 2021 Sep 13. pii: 6369407. doi: 10.1093.
    >> Share

  567. ABOUNADER R, Schiff D
    The blood-brain barrier limits the therapeutic efficacy of antibody drug conjugates in glioblastoma.
    Neuro Oncol. 2021 Sep 13. pii: 6369406. doi: 10.1093.
    >> Share

  568. ZHANG W, Talele S, Sarkaria JN, Elmquist WF, et al
    Changes in the vasculature of human brain tumors: Implications for treatment.
    Neuro Oncol. 2021 Sep 13. pii: 6369378. doi: 10.1093.
    >> Share

  569. IJARE OB, Hambarde S, Brasil da Costa FH, Lopez S, et al
    Glutamine anaplerosis is required for amino acid biosynthesis in human meningiomas.
    Neuro Oncol. 2021 Sep 13. pii: 6369334. doi: 10.1093.
    >> Share

  570. MAROSI C
    Will mastering ferroptosis allow treating refractory meningiomas?
    Neuro Oncol. 2021 Sep 13. pii: 6369228. doi: 10.1093.
    >> Share

  571. DRIVER J, Hoffman SE, Tavakol S, Woodward E, et al
    A Molecularly Integrated Grade for Meningioma.
    Neuro Oncol. 2021 Sep 11. pii: 6368844. doi: 10.1093.
    >> Share

  572. TOM MC, Kotecha R
    Beating a Benchmark: Boron Neutron Capture Therapy for Recurrent and Refractory Meningiomas.
    Neuro Oncol. 2021 Sep 11. pii: 6368846. doi: 10.1093.
    >> Share

  573. IUS T, Ng S, Young JS, Tomasino B, et al
    The benefit of early surgery on overall survival in incidental low grade glioma patients: a multicenter study.
    Neuro Oncol. 2021 Sep 8. pii: 6366593. doi: 10.1093.
    >> Share

  574. SAUNDERS CN, Kinnersley B, Culliford R, Cornish AJ, et al
    Relationship between genetically determined telomere length and glioma risk.
    Neuro Oncol. 2021 Sep 3. pii: 6363706. doi: 10.1093.
    >> Share

  575. WANG D, Veo B, Pierce A, Fosmire S, et al
    A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy.
    Neuro Oncol. 2021 Sep 3. pii: 6363671. doi: 10.1093.
    >> Share

  576. BANDOPADHAYAY P, Chi SN
    The challenges in treating Embryonal Tumors with Multilayered Rosettes (ETMR) and other infant brain tumors.
    Neuro Oncol. 2021 Sep 3. pii: 6363655. doi: 10.1093.
    >> Share

  577. AQUILANTI E, Kageler L, Wen PY, Meyerson M, et al
    Telomerase as a therapeutic target in glioblastoma.
    Neuro Oncol. 2021 Sep 2. pii: 6362724. doi: 10.1093.
    >> Share

  578. BRANDNER S, McAleenan A, Kelly C, Spiga F, et al
    MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review.
    Neuro Oncol. 2021;23:1457-1469.
    >> Share

  579. THACKER N, Bouffet E
    Posterior fossa syndrome-time to unmute the silence on cerebellar mutism.
    Neuro Oncol. 2021;23:1427-1428.
    >> Share

  580. VON HOFF K, Haberler C, Schmitt-Hoffner F, Schepke E, et al
    Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study.
    Neuro Oncol. 2021;23:1597-1611.
    >> Share

  581. KHAN RB, Patay Z, Klimo P, Huang J, et al
    Clinical features, neurologic recovery, and risk factors of postoperative posterior fossa syndrome and delayed recovery: a prospective study.
    Neuro Oncol. 2021;23:1586-1596.
    >> Share

    August 2021
  582. CHUNG C, Brown PD, Wefel JS
    Short reply to "Proton therapy for newly diagnosed glioblastoma: More room for investigation" by R. Press et al.
    Neuro Oncol. 2021 Aug 28. pii: 6359127. doi: 10.1093.
    >> Share

  583. PRESS RH, Chhabra AM, Choi JI, Hasan S, et al
    Proton therapy for newly diagnosed glioblastoma: more room for investigation.
    Neuro Oncol. 2021 Aug 28. pii: 6359128. doi: 10.1093.
    >> Share

  584. CICONE F, Cascini GL, Minniti G
    Reply to: "Letter to the Editor: Assessment of imaging biomarkers in the follow-up of brain metastases after SRS".
    Neuro Oncol. 2021 Aug 24. pii: 6357080. doi: 10.1093.
    >> Share

  585. DERKS SHAE, Jongen JLM, van den Bent MJ, van der Veldt AAM, et al
    Assessment of imaging biomarkers in the follow-up of brain metastases after SRS.
    Neuro Oncol. 2021 Aug 24. pii: 6357079. doi: 10.1093.
    >> Share

  586. RONSLEY R, Bouffet E
    COVID-19 in pediatric cancer: Where are the brain tumors?
    Neuro Oncol. 2021 Aug 20. pii: 6355395. doi: 10.1093.
    >> Share

  587. WANG GM, Cioffi G, Patil N, Waite KA, et al
    Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas.
    Neuro Oncol. 2021 Aug 13. pii: 6350590. doi: 10.1093.
    >> Share

  588. JO J, Donahue J, Sarai G, Petroni G, et al
    Management of Venous Thromboembolism in High-Grade Glioma: Does Low Molecular Weight Heparin Increase Intracranial Bleeding Risk?
    Neuro Oncol. 2021 Aug 12. pii: 6348905. doi: 10.1093.
    >> Share

  589. YANG WC, Chen YF, Yang CC, Wu PF, et al
    Erratum to: Hippocampal avoidance whole-brain radiotherapy without memantine in preserving neurocognitive function for brain metastases: a phase II blinded randomized trial.
    Neuro Oncol. 2021 Aug 7. pii: 6345198. doi: 10.1093.
    >> Share

  590. LAMBA N, Aizer AA
    The evolving role of systemic therapy and local, brain-directed treatment in patients with melanoma and brain metastases.
    Neuro Oncol. 2021 Aug 5. pii: 6341089. doi: 10.1093.
    >> Share

  591. WINKLER F
    Silencing glioblastoma networks to make temozolomide more effective.
    Neuro Oncol. 2021 Aug 4. pii: 6339977. doi: 10.1093.
    >> Share

  592. SU JM, Kilburn LB, Mansur DB, Krailo M, et al
    Phase 1/2 Trial of Vorinostat and Radiation and Maintenance Vorinostat in Children with Diffuse Intrinsic Pontine Glioma: A Children's Oncology Group Report.
    Neuro Oncol. 2021 Aug 4. pii: 6339987. doi: 10.1093.
    >> Share

  593. HUANG H, Georganaki M, Conze LL, Lavina B, et al
    ELTD1-deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma.
    Neuro Oncol. 2021 Aug 4. pii: 6339962. doi: 10.1093.
    >> Share

  594. WEN PY, Packer RJ
    The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications.
    Neuro Oncol. 2021;23:1215-1217.
    >> Share

  595. LOUIS DN, Perry A, Wesseling P, Brat DJ, et al
    The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
    Neuro Oncol. 2021;23:1231-1251.
    >> Share

  596. CORREA DD
    Neurocognitive functions in primary CNS lymphoma.
    Neuro Oncol. 2021;23:1220-1221.
    >> Share

  597. MOSELLA MS, Sabedot TS, Silva TC, Malta TM, et al
    DNA methylation-based signatures classify sporadic pituitary tumors according to clinicopathological features.
    Neuro Oncol. 2021;23:1292-1303.
    >> Share

  598. VAN DER MEULEN M, Dirven L, Habets EJJ, Bakunina K, et al
    Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial.
    Neuro Oncol. 2021;23:1315-1326.
    >> Share

    July 2021
  599. MUNOZ PINTO MF, Campbell SJ, Simoglou Karali C, Johanssen VA, et al
    Selective blood-brain barrier permeabilisation of brain metastases by a type-1 receptor selective tumour necrosis factor mutein.
    Neuro Oncol. 2021 Jul 23. pii: 6326734. doi: 10.1093.
    >> Share

  600. RICHARDSON S, Hill RM, Kui C, Lindsey JC, et al
    Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse.
    Neuro Oncol. 2021 Jul 17. pii: 6323243. doi: 10.1093.
    >> Share

  601. SHIH HA
    An early foray with targeted therapy and inspiring novel approaches to combat adult medulloblastoma.
    Neuro Oncol. 2021 Jul 16. pii: 6323026. doi: 10.1093.
    >> Share

  602. HULSBERGEN AFC, Abunimer AM, Ida F, Kavouridis VK, et al
    Neurosurgical resection for locally recurrent brain metastasis.
    Neuro Oncol. 2021 Jul 16. pii: 6322695. doi: 10.1093.
    >> Share

  603. SHARMA P, Xu J, Williams K, Easley M, et al
    Inhibition of nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of the nicotinamide adenine dinucleotide salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
    Neuro Oncol. 2021 Jul 14. pii: 6321319. doi: 10.1093.
    >> Share

  604. LUDWIG N, Rao A, Sandlesh P, Yerneni SS, et al
    Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles.
    Neuro Oncol. 2021 Jul 13. pii: 6320007. doi: 10.1093.
    >> Share

  605. RAMASWAMY V, Bartels U
    Selumetinib for optic pathway glioma: Seeing through the fog, (not yet) the end of the tunnel?
    Neuro Oncol. 2021 Jul 12. pii: 6319139. doi: 10.1093.
    >> Share

  606. BALANA C, Sun C, Vaz MA, Esteve A, et al
    Reply to: Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?
    Neuro Oncol. 2021 Jul 9. pii: 6318238. doi: 10.1093.
    >> Share

  607. TERABE M, Wu J
    Rethinking Immunotherapy in Meningiomas.
    Neuro Oncol. 2021 Jul 9. pii: 6318447. doi: 10.1093.
    >> Share

  608. ZHAO B, Ma W
    Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?
    Neuro Oncol. 2021 Jul 9. pii: 6318242. doi: 10.1093.
    >> Share

  609. BAGLEY SJ, Kline CN
    Understanding the global impact of primary brain tumors: the untapped potential of population-based cancer registries.
    Neuro Oncol. 2021 Jul 9. pii: 6318451. doi: 10.1093.
    >> Share

  610. LUKAS RV
    Essential Oils for Blood-Brain Barrier Disruption: Preclinical Studies of NEO100 in Breast Cancer Brain Metastases.
    Neuro Oncol. 2021 Jul 9. pii: 6318449. doi: 10.1093.
    >> Share

  611. ALHALABI OT, Fletcher MNC, Hielscher T, Kessler T, et al
    A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma.
    Neuro Oncol. 2021 Jul 7. pii: 6316731. doi: 10.1093.
    >> Share

  612. TONOGAI EJ, Huang S, Botham RC, Berry MR, et al
    Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients.
    Neuro Oncol. 2021 Jul 3. pii: 6314291. doi: 10.1093.
    >> Share

  613. TEHRANIAN C, Fankhauser L, Harter PN, Ratcliffe CDH, et al
    The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis.
    Neuro Oncol. 2021 Jul 3. pii: 6314211. doi: 10.1093.
    >> Share

  614. PETRIDIS PD, Horenstein C, Pereira B, Wu P, et al
    BOLD Asynchrony Elucidates Tumor Burden in IDH-Mutated Gliomas.
    Neuro Oncol. 2021 Jul 2. pii: 6313213. doi: 10.1093.
    >> Share

  615. YAMAZAKI S, Ohka F, Hirano M, Shiraki Y, et al
    Newly Established Patient-derived Organoid Model of Intracranial Meningioma.
    Neuro Oncol. 2021 Jul 2. pii: 6313216. doi: 10.1093.
    >> Share

  616. D'ALESSANDRIS QG, Della Pepa GM, Noya C, Olivi A, et al
    Mesenchymal stem cells: are they the good or the bad?
    Neuro Oncol. 2021;23:1203-1204.
    >> Share

  617. DANKNER M, Maritan SM
    The relevance of surgical status in nodular leptomeningeal metastasis patient outcomes.
    Neuro Oncol. 2021;23:1207.
    >> Share

  618. LE RHUN E, Devos P, Weller J, Seystahl K, et al
    Prognostic factors in leptomeningeal metastases.
    Neuro Oncol. 2021;23:1208-1209.
    >> Share

  619. BARAJAS RF, Politi LS, Anzalone N, Schoder H, et al
    Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG).
    Neuro Oncol. 2021;23:1056-1071.
    >> Share

  620. LE RHUN E, Devos P, Weller J, Seystahl K, et al
    Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors.
    Neuro Oncol. 2021;23:1100-1112.
    >> Share

  621. FORDE C, King AT, Rutherford SA, Hammerbeck-Ward C, et al
    Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution.
    Neuro Oncol. 2021;23:1113-1124.
    >> Share

    June 2021
  622. GOLDBRUNNER R, Stavrinou P, Jenkinson MD, Sahm F, et al
    EANO guideline on the diagnosis and management of meningiomas.
    Neuro Oncol. 2021 Jun 28. pii: 6310843. doi: 10.1093.
    >> Share

  623. WALBERT T, Harrison RA, Schiff D, Avila EK, et al
    SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors.
    Neuro Oncol. 2021 Jun 26. pii: 6310125. doi: 10.1093.
    >> Share

  624. PENG J, Kim DD, Patel JB, Zeng X, et al
    Deep Learning-Based Automatic Tumor Burden Assessment of Pediatric High-Grade Gliomas, Medulloblastomas, and Other Leptomeningeal Seeding Tumors.
    Neuro Oncol. 2021 Jun 26. pii: 6310123. doi: 10.1093.
    >> Share

  625. WIRSCHING HG, Steiner L, Becker D, Regli L, et al
    Increase in contrast-enhancing volume of irradiated meningiomas reflects tumor progression and not pseudoprogression.
    Neuro Oncol. 2021 Jun 19. pii: 6305986. doi: 10.1093.
    >> Share

  626. JOHNSON KC, Verhaak RGW
    Serum cell-free DNA epigenetic biomarkers aid glioma diagnostics and monitoring.
    Neuro Oncol. 2021 Jun 17. pii: 6302547. doi: 10.1093.
    >> Share

  627. HAU P
    Dissecting adult SHH-activated medulloblastoma - molecularly defined tumor subsets reveal new prognostic biomarkers.
    Neuro Oncol. 2021 Jun 17. pii: 6302543. doi: 10.1093.
    >> Share

  628. SHAH AH, Gilbert M, Ivan ME, Komotar RJ, et al
    The role of human endogenous retroviruses in gliomas: from etiological perspectives and therapeutic implications.
    Neuro Oncol. 2021 Jun 12. pii: 6297568. doi: 10.1093.
    >> Share

  629. ERKER C, Lane A, Chaney B, Leary S, et al
    Characteristics of Patients >/= 10 Years of Age with Diffuse Intrinsic Pontine Glioma: A Report from the International DIPG Registry.
    Neuro Oncol. 2021 Jun 11. pii: 6296498. doi: 10.1093.
    >> Share

  630. SHEEHAN J, Pikis S, Islim A, Chen CJ, et al
    An International Multicenter Matched Cohort Analysis of Incidental Meningioma Progression During Active Surveillance or After Stereotactic Radiosurgery: The IMPASSE Study.
    Neuro Oncol. 2021 Jun 9. pii: 6295369. doi: 10.1093.
    >> Share

  631. KOTECHA R, Aboian M, Nabavizadeh SA, Parent EE, et al
    Letter regarding "Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients-a report of the PET/RANO group": 18F-fluciclovine and target volume delineation.
    Neuro Oncol. 2021 Jun 3. pii: 6291736. doi: 10.1093.
    >> Share

  632. GALLDIKS N, Niyazi M, Tonn JC, Langen KJ, et al
    Reply to the letter regarding "Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients-a report of the PET/RANO group": 18F-fluciclovine and target volume delineation.
    Neuro Oncol. 2021 Jun 3. pii: 6291737. doi: 10.1093.
    >> Share

  633. RIEMONDY KA, Venkataraman S, Willard N, Nellan A, et al
    Neoplastic and immune single cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma.
    Neuro Oncol. 2021 Jun 2. pii: 6291352. doi: 10.1093.
    >> Share

  634. RITZMANN TA, Kilday JP, Grundy RG
    Pediatric ependymomas: destined to recur?
    Neuro Oncol. 2021;23:874-876.
    >> Share

  635. POON MTC, Brennan PM, Jin K, Sudlow CLM, et al
    Might changes in diagnostic practice explain increasing incidence of brain and central nervous system tumors? A population-based study in Wales (United Kingdom) and the United States.
    Neuro Oncol. 2021;23:979-989.
    >> Share

  636. ADOLPH JE, Fleischhack G, Mikasch R, Zeller J, et al
    Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study.
    Neuro Oncol. 2021;23:1012-1023.
    >> Share

    May 2021
  637. PHILLIPS LM, Li S, Gumin J, Daou M, et al
    An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus.
    Neuro Oncol. 2021 May 31. pii: 6290257. doi: 10.1093.
    >> Share

  638. MARIN BM, Porath KA, Jain S, Kim M, et al
    Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.
    Neuro Oncol. 2021 May 29. pii: 6288409. doi: 10.1093.
    >> Share

  639. SCOCCIANTI S, Olmetto E, Pinzi V, Osti MF, et al
    Immunotherapy in association with stereotactic radiotherapy for Non-Small Cell Lung Cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO.
    Neuro Oncol. 2021 May 29. pii: 6288399. doi: 10.1093.
    >> Share

  640. VERBURG N, Barthel FP, Anderson KJ, Johnson KC, et al
    Spatial concordance of DNA methylation classification in diffuse glioma.
    Neuro Oncol. 2021 May 28. pii: 6287958. doi: 10.1093.
    >> Share

  641. SIMOVIC M, Bolkestein M, Moustafa M, Wong JKL, et al
    Carbon ion radiotherapy eradicates medulloblastomas with chromothripsis in an orthotopic Li-Fraumeni patient-derived mouse model.
    Neuro Oncol. 2021 May 28. pii: 6287957. doi: 10.1093.
    >> Share

  642. DE ANDRADE COSTA A, Chatterjee J, Cobb O, Sanapala S, et al
    RNA sequence analysis reveals ITGAL/CD11A as a stromal regulator of murine low-grade glioma growth.
    Neuro Oncol. 2021 May 27. pii: 6286081. doi: 10.1093.
    >> Share

  643. LI Y, Wang X, Qi S, Gao L, et al
    Spliceosome-regulated RSRP1-dependent NF-kappaB activation promotes the glioblastoma mesenchymal phenotype.
    Neuro Oncol. 2021 May 27. pii: 6286882. doi: 10.1093.
    >> Share

  644. LAPERRIERE NJ
    Protons for the Management of Adult Patients with Glioblastoma.
    Neuro Oncol. 2021 May 24. pii: 6283746. doi: 10.1093.
    >> Share

  645. MENDOZA TR
    Especially for neuro-oncologists - minimally important differences for the EORTC QLQ-C30 in glioma patients.
    Neuro Oncol. 2021 May 24. pii: 6283743. doi: 10.1093.
    >> Share

  646. CHONGSATHIDKIET P, Fecci PE
    Cold-inducible RNA-binding protein (CIRBP) as a biomarker to predict recurrence of brain metastases.
    Neuro Oncol. 2021 May 24. pii: 6283744. doi: 10.1093.
    >> Share

  647. BI WL, Nayak L, Meredith DM, Driver J, et al
    Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma: Phase II trial results.
    Neuro Oncol. 2021 May 20. pii: 6279078. doi: 10.1093.
    >> Share

  648. GUSYATINER O, Bady P, Pham MDT, Lei Y, et al
    BET inhibitors repress expression of Interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma.
    Neuro Oncol. 2021 May 14. pii: 6275457. doi: 10.1093.
    >> Share

  649. SIM HW, McDonald KL, Lwin Z, Barnes EH, et al
    A randomized phase II trial of veliparib, radiotherapy and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.
    Neuro Oncol. 2021 May 13. pii: 6275307. doi: 10.1093.
    >> Share

  650. DAHL NA, Vibhakar R
    Converging evidence for inhibition of transcriptional control in high-grade gliomas.
    Neuro Oncol. 2021 May 13. pii: 6275360. doi: 10.1093.
    >> Share

  651. TAKAI S, Wanibuchi M, Kawabata S, Takeuchi K, et al
    Reactor-based boron neutron capture therapy for 44 cases of recurrent and refractory high-grade meningiomas with long-term follow-up.
    Neuro Oncol. 2021 May 13. pii: 6275296. doi: 10.1093.
    >> Share

  652. BAO Z, Hua L, Ye Y, Wang D, et al
    MEF2C silencing downregulates NF2 and E-cadherin and enhances Erastin-induced ferroptosis in meningioma.
    Neuro Oncol. 2021 May 13. pii: 6275374. doi: 10.1093.
    >> Share

  653. WANG Z, Gao L, Wang Y, Chang M, et al
    Validation of the prognostic value of 9-gene ATE score for IDH wild-type glioblastoma.
    Neuro Oncol. 2021 May 13. pii: 6275034. doi: 10.1093.
    >> Share

  654. NASSIRI F, Wang JZ, Singh O, Karimi S, et al
    Loss of H3K27me3 in meningiomas.
    Neuro Oncol. 2021 May 10. pii: 6273127. doi: 10.1093.
    >> Share

  655. FELKER J, Agnihotri S
    Not all mouse blood-brain barriers are created equal.
    Neuro Oncol. 2021;23:705-706.
    >> Share

  656. SO J, Mamatjan Y, Zadeh G, Aldape K, et al
    Transcription factor networks of oligodendrogliomas treated with adjuvant radiotherapy or observation inform prognosis.
    Neuro Oncol. 2021;23:795-802.
    >> Share

  657. MASSIMINO M, Barretta F, Modena P, Witt H, et al
    Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up.
    Neuro Oncol. 2021;23:848-857.
    >> Share

  658. CLAUS EB, Cannataro VL, Gaffney SG, Townsend JP, et al
    Environmental and sex-specific molecular signatures of glioma causation.
    Neuro Oncol. 2021 May 4. pii: 6263733. doi: 10.1093.
    >> Share

    April 2021
  659. BRANDNER S, McAleenan A, Kelly C, Spiga F, et al
    MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Review.
    Neuro Oncol. 2021 Apr 30. pii: 6263562. doi: 10.1093.
    >> Share

  660. YEUNG J, Yaghoobi V, Miyagishima D, Vesely MD, et al
    Targeting the CSF1/CSF1R Axis is a Potential Treatment Strategy for Malignant Meningiomas.
    Neuro Oncol. 2021 Apr 29. pii: 6259024. doi: 10.1093.
    >> Share

  661. TESILEANU CMS, van den Bent MJ, Sanson M, Wick W, et al
    Prognostic significance of genome-wide DNA methylation profiles within the randomised, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.
    Neuro Oncol. 2021 Apr 29. pii: 6259004. doi: 10.1093.
    >> Share

  662. LAMBA N, Wen PY, Aizer AA
    Epidemiology of Brain Metastases and Leptomeningeal Disease.
    Neuro Oncol. 2021 Apr 28. pii: 6256866. doi: 10.1093.
    >> Share

  663. STROTHER D, Lafay-Cousin L
    Adjuvant therapy for high risk medulloblastoma: More is better?
    Neuro Oncol. 2021 Apr 27. pii: 6254485. doi: 10.1093.
    >> Share

  664. MARINELLI JP, Carlson ML
    Potential for selection bias surrounding reporting of benign brain tumors in the United States.
    Neuro Oncol. 2021 Apr 26. pii: 6253739. doi: 10.1093.
    >> Share

  665. TAWBI HA, Forsyth PA, Hodi FS, Lao CD, et al
    Safety and Efficacy of the Combination of Nivolumab Plus Ipilimumab in Patients With Melanoma and Asymptomatic or Symptomatic Brain Metastases (CheckMate 204).
    Neuro Oncol. 2021 Apr 21. pii: 6242717. doi: 10.1093.
    >> Share

  666. NICLOU SP, Golebiewska A
    Turning strength into weakness: protein degradation and autophagy as therapeutic targets in Glioblastoma?
    Neuro Oncol. 2021 Apr 17. pii: 6231737. doi: 10.1093.
    >> Share

  667. SCHNEIDER M, Vollmer L, Potthoff AL, Ravi VM, et al
    Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma.
    Neuro Oncol. 2021 Apr 17. pii: 6231712. doi: 10.1093.
    >> Share

  668. VISWANATH P, Batsios G, Ayyappan V, Taglang C, et al
    Metabolic imaging detects elevated glucose flux through the pentose phosphate pathway associated with TERT expression in low-grade gliomas.
    Neuro Oncol. 2021 Apr 17. pii: 6231711. doi: 10.1093.
    >> Share

  669. VOLMAR MNM, Cheng J, Alenezi H, Richter S, et al
    Cannabidiol converts NFkappaB into a tumor suppressor in glioblastoma with defined antioxidative properties.
    Neuro Oncol. 2021 Apr 17. pii: 6231710. doi: 10.1093.
    >> Share

  670. KATSUSHIMA K, Lee B, Kunhiraman H, Zhong C, et al
    The long noncoding RNA lnc-HLX-2-7 is oncogenic in Group 3 medulloblastomas.
    Neuro Oncol. 2021;23:572-585.
    >> Share

  671. THOMAS C, Soschinski P, Zwaig M, Oikonomopoulos S, et al
    The genetic landscape of choroid plexus tumors in children and adults.
    Neuro Oncol. 2021;23:650-660.
    >> Share

  672. WANIS HA, Moller H, Ashkan K, Davies EA, et al
    The incidence of major subtypes of primary brain tumours in adults in England 1995-2017.
    Neuro Oncol. 2021 Apr 9. pii: 6218679. doi: 10.1093.
    >> Share

  673. HORBINSKI C, McCortney K, Stupp R
    MGMT promoter methylation is associated with patient age and 1p/19q status in IDH-mutant gliomas.
    Neuro Oncol. 2021 Apr 8. pii: 6217333. doi: 10.1093.
    >> Share

  674. MUKHERJEE S, Schiltz G, Clutter M, Mishra R, et al
    Erratum to: DDIS-27. TARGETING ATP DOCKING AND P35/P25 BINDING OF CDK5 IN GLIOMA STEM CELLS USING SYNTHETIC INHIBITORS.
    Neuro Oncol. 2021 Apr 7. pii: 6214067. doi: 10.1093.
    >> Share

  675. MUKHERJEE S, Olson C, Dundar B, Sharma N, et al
    Erratum to: STEM-19. RESISTANCE IS FUTILE: UNDERSTANDING AND TARGETING THE CDK5-CREB1-MCL1 AXIS TO PREVENT RADIATION RESISTANCE IN GLIOMA STEM CELLS.
    Neuro Oncol. 2021 Apr 7. pii: 6214066. doi: 10.1093.
    >> Share

  676. FRAPPAZ D, Barritault M, Montane L, Laigle-Donadey F, et al
    MEVITEM - A Phase I/II of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.
    Neuro Oncol. 2021 Apr 7. pii: 6213882. doi: 10.1093.
    >> Share

  677. YU Y, Villanueva-Meyer J, Grimmer MR, Hilz S, et al
    Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
    Neuro Oncol. 2021 Apr 5. pii: 6211336. doi: 10.1093.
    >> Share

  678. SANTAGATA S, Ligon KL
    Prognostication for meningiomas: H3K27me3 to the rescue?
    Neuro Oncol. 2021 Apr 3. pii: 6209863. doi: 10.1093.
    >> Share

  679. TSANG DS, Schulte F
    Beyond the brain: Socioeconomic status and race in pediatric brain tumor survivorship.
    Neuro Oncol. 2021 Apr 3. pii: 6209877. doi: 10.1093.
    >> Share

  680. LEE EQ, Selig W, Meehan C, Bacha J, et al
    Report of National Brain Tumor Society Roundtable Workshop on Innovating Brain Tumor Clinical Trials: Building on Lessons Learned from COVID-19 Experience.
    Neuro Oncol. 2021 Apr 2. pii: 6209406. doi: 10.1093.
    >> Share

    March 2021
  681. PERKINS S, Acharya S
    Radiation therapy to the developing brain: advanced technology is ready for robust optimization parameters.
    Neuro Oncol. 2021;23:350-351.
    >> Share

  682. LASSMAN AB, Cloughesy TF
    Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile?
    Neuro Oncol. 2021;23:347-349.
    >> Share

  683. KUMTHEKAR P, Dunbar EM, Peters KB, Brastianos PK, et al
    A broad perspective on evaluating bias in the neuro-oncology workplace.
    Neuro Oncol. 2021;23:498-499.
    >> Share

  684. GILBERT MR, Yuan Y, Wu J, Mendoza T, et al
    A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma.
    Neuro Oncol. 2021;23:468-477.
    >> Share

  685. JAECKLE KA, Ballman KV, van den Bent M, Giannini C, et al
    CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design.
    Neuro Oncol. 2021;23:457-467.
    >> Share

  686. BOURDEAUT F
    Are B7-H3 CAR-T cells the future universal treatment for pediatric brain tumors?
    Neuro Oncol. 2021 Mar 23. pii: 6182498. doi: 10.1093.
    >> Share

  687. LU SL, Xiao FR, Cheng JC, Yang WC, et al
    Randomized Multi-Reader Evaluation of Automated Detection and Segmentation of Brain Tumors in Stereotactic Radiosurgery with Deep Neural Networks.
    Neuro Oncol. 2021 Mar 23. pii: 6180141. doi: 10.1093.
    >> Share

  688. LATHIA JD
    Fountain of chaos: cerebrospinal fluid enhancement of cancer stem cells in glioblastoma.
    Neuro Oncol. 2021 Mar 22. pii: 6179836. doi: 10.1093.
    >> Share

  689. NOBRE L, Ramaswamy V
    Medulloblastoma (cross)talk through extracellular vesicles.
    Neuro Oncol. 2021 Mar 22. pii: 6179837. doi: 10.1093.
    >> Share

  690. OSTROM QT, Edelson J, Byun J, Han Y, et al
    Partitioned glioma heritability shows subtype-specific enrichment in immune cells.
    Neuro Oncol. 2021 Mar 20. pii: 6179266. doi: 10.1093.
    >> Share

  691. GIRARDI F, Rous B, Stiller CA, Gatta G, et al
    The histology of brain tumours for 67,331 children and 671,085 adults diagnosed in 60 countries during 2000-2014: a global, population-based study (CONCORD-3).
    Neuro Oncol. 2021 Mar 19. pii: 6178525. doi: 10.1093.
    >> Share

  692. VERKOUTEREN BJA, Cosgun B, Vermeulen RJ, Reinders MGHC, et al
    Prevalence of medulloblastoma in basal cell nevus syndrome patients with a PTCH1 mutation.
    Neuro Oncol. 2021 Mar 17. pii: 6231902. doi: 10.1093.
    >> Share

  693. TSIEN C
    Stereotactic radiation therapy with concurrent immunotherapy for recurrent glioblastoma-hope or hype?
    Neuro Oncol. 2021 Mar 12. pii: 6168946. doi: 10.1093.
    >> Share

  694. WINKLER F
    In glioma, all endothelial cells are not created the same.
    Neuro Oncol. 2021 Mar 11. pii: 6168415. doi: 10.1093.
    >> Share

  695. SAIT SF, Karajannis MA
    Pediatric spinal cord gliomas - low grade but high risk for recurrence: should we treat them differently from intracranial low-grade gliomas?
    Neuro Oncol. 2021 Mar 11. pii: 6168346. doi: 10.1093.
    >> Share

  696. TRIFILETTI DM, Brown PD
    Cognitive outcomes in patients with low-grade glioma.
    Neuro Oncol. 2021 Mar 11. pii: 6168225. doi: 10.1093.
    >> Share

  697. FONSECA A, Bouffet E
    Brainstem Gliomas... The Devil is in the Details.
    Neuro Oncol. 2021 Mar 11. pii: 6168340. doi: 10.1093.
    >> Share

  698. BAUMERT BG, Pesce GA
    Elderly patients with brain metastases: new support for the balancing act in treatment decision making.
    Neuro Oncol. 2021 Mar 11. pii: 6168221. doi: 10.1093.
    >> Share

  699. MENG Y, Pople CB, Suppiah S, Llinas M, et al
    MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors.
    Neuro Oncol. 2021 Mar 10. pii: 6167330. doi: 10.1093.
    >> Share

  700. LIM-FAT MJ, Maralani PJ
    Is there an optimal MRI surveillance schedule for patients with high grade glioma after standard of care therapy?
    Neuro Oncol. 2021 Mar 1. pii: 6155531. doi: 10.1093.
    >> Share

  701. SPERDUTO PW, Lou E
    The Past, Current and Future Management of Brain Metastases in EGFR-Mutant Non-Small Cell Lung Cancer.
    Neuro Oncol. 2021 Mar 1. pii: 6155599. doi: 10.1093.
    >> Share

    February 2021
  702. GIANNINI C, Giangaspero F
    TERT promoter mutation: is it enough to call a WHO grade II astrocytoma IDH-wildtype glioblastoma?
    Neuro Oncol. 2021 Feb 28. pii: 6154503. doi: 10.1093.
    >> Share

  703. WANG W, He H, Marin-Ramos NI, Zeng S, et al
    Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer.
    Neuro Oncol. 2021 Feb 28. pii: 6154448. doi: 10.1093.
    >> Share

  704. BROWN PD, Chung C, Liu DD, McAvoy S, et al
    A Prospective Phase II Randomized Trial of Proton Radiotherapy vs. Intensity Modulated Radiotherapy for Patients with Newly Diagnosed Glioblastoma.
    Neuro Oncol. 2021 Feb 27. pii: 6154000. doi: 10.1093.
    >> Share

  705. JESSURUN CAC, Hulsbergen AFC, de Wit AE, Tewarie IA, et al
    The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis.
    Neuro Oncol. 2021 Feb 25. pii: 6150018. doi: 10.1093.
    >> Share

  706. FANGUSARO J, Onar-Thomas A, Poussaint TY, Wu S, et al
    A Phase 2 Trial of Selumetinib in Children with Recurrent Optic Pathway and Hypothalamic Low-Grade Glioma without NF1: A Pediatric Brain Tumor Consortium Study.
    Neuro Oncol. 2021 Feb 25. pii: 6149924. doi: 10.1093.
    >> Share

  707. TSCHERNICHOVSKY R, Katz LH, Derazne E, Berliner MB, et al
    Height in Adolescence as a Risk Factor for Glioma Subtypes: a Nationwide Retrospective Cohort Study of 2.2 Million Subjects.
    Neuro Oncol. 2021 Feb 25. pii: 6149925. doi: 10.1093.
    >> Share

  708. JAIN R, Chi AS
    Radiogenomics identifying important biological pathways in gliomas.
    Neuro Oncol. 2021;23:177-178.
    >> Share

  709. ELLINGSON BM, Brown MS, Boxerman JL, Gerstner ER, et al
    Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials.
    Neuro Oncol. 2021;23:189-198.
    >> Share

  710. KANAMORI M, Takami H, Yamaguchi S, Sasayama T, et al
    So-called bifocal tumors with diabetes insipidus and negative tumor markers: are they all germinoma?
    Neuro Oncol. 2021;23:295-303.
    >> Share

  711. CANNON-ALBRIGHT LA, Farnham JM, Stevens J, Teerlink CC, et al
    Genome-wide analysis of high-risk primary brain cancer pedigrees identifies PDXDC1 as a candidate brain cancer predisposition gene.
    Neuro Oncol. 2021;23:277-283.
    >> Share

  712. MATHEN P, Smart DK
    Reimagining External Beam Radiotherapy for Glioblastoma: "Old Beam, New Trick".
    Neuro Oncol. 2021 Feb 22. pii: 6146614. doi: 10.1093.
    >> Share

  713. KIM MM, Aryal MP, Sun Y, Parmar HA, et al
    Response assessment during chemoradiation using a hypercellular/hyperperfused imaging phenotype predicts survival in patients with newly diagnosed glioblastoma.
    Neuro Oncol. 2021 Feb 18. pii: 6144576. doi: 10.1093.
    >> Share

  714. DIRVEN L, Musoro JZ, Coens C, Reijneveld JC, et al
    Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients.
    Neuro Oncol. 2021 Feb 18. pii: 6142946. doi: 10.1093.
    >> Share

  715. KORSHUNOV A, Okonechnikov K, Stichel D, Ryzhova M, et al
    Integrated molecular analysis of adult Sonic Hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with VEGFA as potent prognostic indicator.
    Neuro Oncol. 2021 Feb 16. pii: 6137557. doi: 10.1093.
    >> Share

  716. HUANG T, Cheng SY
    Targeting phospholipid metabolism for glioblastoma therapy.
    Neuro Oncol. 2021 Feb 9. pii: 6131652. doi: 10.1093.
    >> Share

  717. SCHAFFENRATH J, Wyss T, He L, Rushing EJ, et al
    Blood-brain barrier alterations in human brain tumors revealed by genome-wide transcriptomic profiling.
    Neuro Oncol. 2021 Feb 9. pii: 6131739. doi: 10.1093.
    >> Share

  718. SABEDOT T, Malta T, Snyder J, Nelson K, et al
    A serum-based DNA methylation assay provides accurate detection of glioma.
    Neuro Oncol. 2021 Feb 9. pii: 6131768. doi: 10.1093.
    >> Share

  719. GRAILLON T, Ferrer L, Siffre J, Sanson M, et al
    Role of 3-D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study.
    Neuro Oncol. 2021 Feb 8. pii: 6131353. doi: 10.1093.
    >> Share

  720. GUO X, Wang S, Wang Y, Ma W, et al
    Anti-PD-1 plus anti-VEGF therapy in multiple intracranial metastases of a hypermutated, IDH wild-type glioblastoma.
    Neuro Oncol. 2021 Feb 8. pii: 6131355. doi: 10.1093.
    >> Share

  721. YAMAMOTO M, Sanomachi T, Suzuki S, Uchida H, et al
    Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma.
    Neuro Oncol. 2021 Feb 8. pii: 6131352. doi: 10.1093.
    >> Share

  722. OTANI Y, Sur H, Rachaiah G, Namagiri S, et al
    Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
    Neuro Oncol. 2021 Feb 8. pii: 6131351. doi: 10.1093.
    >> Share

  723. TORRES VA, Ashford JM, Wright E, Xu J, et al
    The Impact of Socioeconomic Status (SES) on Cognitive Outcomes Following Radiotherapy for Pediatric Brain Tumors: A Prospective, Longitudinal Trial.
    Neuro Oncol. 2021 Feb 5. pii: 6128895. doi: 10.1093.
    >> Share

  724. LIAO Y, Luo Z, Deng Y, Zhang F, et al
    OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes.
    Neuro Oncol. 2021 Feb 4. pii: 6128721. doi: 10.1093.
    >> Share

  725. GALLDIKS N, Niyazi M, Grosu AL, Kocher M, et al
    Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group.
    Neuro Oncol. 2021 Feb 4. pii: 6128548. doi: 10.1093.
    >> Share

    January 2021
  726. WEFEL JS, Armstrong TS, Pugh SL, Gilbert MR, et al
    Neurocognitive, Symptom, and Health- Related Quality of Life Outcomes of a Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma (NRG/RTOG 0825).
    Neuro Oncol. 2021 Jan 30. pii: 6124000. doi: 10.1093.
    >> Share

  727. YANG TJ, Wijetunga NA, Yamada J, Wolden S, et al
    Clinical trial of proton craniospinal irradiation for leptomeningeal metastases.
    Neuro Oncol. 2021;23:134-143.
    >> Share

  728. NARITA Y, Nagane M, Mishima K, Terui Y, et al
    Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
    Neuro Oncol. 2021;23:122-133.
    >> Share

  729. MAIRE CL, Fuh MM, Kaulich K, Fita KD, et al
    Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification.
    Neuro Oncol. 2021 Jan 28. pii: 6122789. doi: 10.1093.
    >> Share

  730. GERRITSEN JKW, Vincent AJPE, De Vleeschouwer S
    Maximizing extent of resection while minimizing the risk of neurological morbidity in glioma patients: a novel grading scale to translate these surgical goals into a merged onco-functional clinical outcome.
    Neuro Oncol. 2021 Jan 20. pii: 6104892. doi: 10.1093.
    >> Share

  731. VARGAS LOPEZ AJ
    Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
    Neuro Oncol. 2021 Jan 20. pii: 6104916. doi: 10.1093.
    >> Share

  732. DIAMANDIS P
    De-coding group 3 medulloblastoma biology with non-coding RNA.
    Neuro Oncol. 2021 Jan 20. pii: 6104902. doi: 10.1093.
    >> Share

  733. KATAGI H, Takata N, Aoi Y, Zhang Y, et al
    Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.
    Neuro Oncol. 2021 Jan 20. pii: 6104638. doi: 10.1093.
    >> Share

  734. WEN PY, Weller M, Chiocca EA, Lim M, et al
    Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez.
    Neuro Oncol. 2021 Jan 20. pii: 6104896. doi: 10.1093.
    >> Share

  735. FULTS DW
    Stemming the growth of pediatric gliomas through histone modification.
    Neuro Oncol. 2021 Jan 20. pii: 6104497. doi: 10.1093.
    >> Share

  736. DMYTRIW AA, Huang RY
    In search of predictive and response markers in antiangiogenic therapy of glioblastoma.
    Neuro Oncol. 2021 Jan 20. pii: 6104491. doi: 10.1093.
    >> Share

  737. DANKNER M, Caron M, Al-Saadi T, Yu W, et al
    Invasive growth associated with Cold-Inducible RNA-Binding Protein expression drives recurrence of surgically resected brain metastases.
    Neuro Oncol. 2021 Jan 12. pii: 6089125. doi: 10.1093.
    >> Share

  738. WU S, Li X, Gao F, de Groot JF, et al
    PARP mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
    Neuro Oncol. 2021 Jan 12. pii: 6089123. doi: 10.1093.
    >> Share

  739. BENITEZ JA, Finlay D, Castanza A, Parisian AD, et al
    Pten Deficiency Leads To Proteasome Addiction, A Novel Vulnerability In Glioblastoma.
    Neuro Oncol. 2021 Jan 11. pii: 6081306. doi: 10.1093.
    >> Share

  740. GUTMAN DC, Young RJ
    IDH glioma radiogenomics in the era of deep learning.
    Neuro Oncol. 2021 Jan 8. pii: 6068851. doi: 10.1093.
    >> Share

  741. SNUDERL M
    Molecular classification and deconvolution of the immune microenvironment in glioblastoma.
    Neuro Oncol. 2021 Jan 4. pii: 6062458. doi: 10.1093.
    >> Share

  742. SHOFUDA T, Kanemura Y
    HDACs and MYC in medulloblastoma: how do HDAC inhibitors control MYC-amplified tumors?
    Neuro Oncol. 2021 Jan 4. pii: 6062389. doi: 10.1093.
    >> Share

    December 2020
  743. SHAHZAD U, Taccone MS, Kumar SA, Okura H, et al
    Modeling human brain tumours in flies, worms, and zebrafish: From proof of principle to novel therapeutic targets.
    Neuro Oncol. 2020 Dec 30. pii: 6055605. doi: 10.1093.
    >> Share

  744. DUFOUR C, Foulon S, Geoffray A, Masliah-Planchon J, et al
    Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase 2 trial PNET HR+5.
    Neuro Oncol. 2020 Dec 30. pii: 6055191. doi: 10.1093.
    >> Share

  745. CHUNTOVA P, Chow F, Watchmaker P, Galvez M, et al
    Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology.
    Neuro Oncol. 2020 Dec 24. pii: 6047273. doi: 10.1093.
    >> Share

  746. BEHLING F, Fodi C, Gepfner-Tuma I, Kaltenbach K, et al
    H3K27me3 loss indicates an increased risk of recurrence in the Tubingen meningioma cohort.
    Neuro Oncol. 2020 Dec 24. pii: 6046432. doi: 10.1093.
    >> Share

  747. KUKSIS M, Gao Y, Tran W, Hoey C, et al
    The Incidence of Brain Metastases Among Patients with Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
    Neuro Oncol. 2020 Dec 23. pii: 6046194. doi: 10.1093.
    >> Share

  748. CARLSON JC, Cantu-Gutierrez M, Lozzi B, Huang-Hobbs E, et al
    Identification of diverse tumor endothelial cell populations in malignant glioma.
    Neuro Oncol. 2020 Dec 23. pii: 6046199. doi: 10.1093.
    >> Share

  749. PATIL N, Kelly ME, Yeboa DN, Buerki RA, et al
    Epidemiology of Brainstem High-Grade Gliomas in Children and Adolescents in the United States, 2000-2017.
    Neuro Oncol. 2020 Dec 21. pii: 6042829. doi: 10.1093.
    >> Share

  750. PERWEIN T, Benesch M, Kandels D, Pietsch T, et al
    High frequency of disease progression in pediatric spinal cord low-grade glioma (LGG): Management strategies and results from the German LGG study group.
    Neuro Oncol. 2020 Dec 21. pii: 6042812. doi: 10.1093.
    >> Share

  751. BERNHARDT D, Combs SE
    Reply to: "Call of duty: neuro-oncology outpatient management during the COVID-19 pandemic in Milan, Italy".
    Neuro Oncol. 2020;22:1893.
    >> Share

  752. YANG Z, Zhang Y, Li R, Yisikandaer A, et al
    Whole Brain Radiotherapy With and Without Concurrent Erlotinib in NSCLC with Brain Metastases: a multicentre, open-label, randomized, controlled phase 3 Trial.
    Neuro Oncol. 2020 Dec 17. pii: 6040795. doi: 10.1093.
    >> Share

  753. LIU Y, Li Z, Zhang M, Zhou H, et al
    Rolling-translated EGFR Variants Sustain EGFR Signaling and Promote Glioblastoma Tumorigenicity.
    Neuro Oncol. 2020 Dec 16. pii: 6039055. doi: 10.1093.
    >> Share

  754. HAYDAR D, Houke H, Chiang J, Yi Z, et al
    Cell surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery.
    Neuro Oncol. 2020 Dec 15. pii: 6035165. doi: 10.1093.
    >> Share

  755. XIE R, Kessler T, Grosch J, Hai L, et al
    Tumor cell network integration in glioma represents a stemness feature.
    Neuro Oncol. 2020 Dec 15. pii: 6035154. doi: 10.1093.
    >> Share

  756. PUDUVALLI VK
    Demystifying Demethylator Sensitivity in Gliomas: Role for TERT and DNMT1.
    Neuro Oncol. 2020 Dec 2. pii: 6017324. doi: 10.1093.
    >> Share

  757. HUANG J, Mehta M
    Can proton therapy reduce radiation-related lymphopenia in glioblastoma?
    Neuro Oncol. 2020 Dec 2. pii: 6017294. doi: 10.1093.
    >> Share

  758. GENOVESI LA, Puttick S, Millar A, Kojic M, et al
    Patient derived orthotopic xenograft models of Medulloblastoma lack a functional blood brain barrier.
    Neuro Oncol. 2020 Dec 1. pii: 6015057. doi: 10.1093.
    >> Share

  759. YUAN M, White D, Resar L, Bar E, et al
    Conditional reprograming culture conditions facilitate growth of lower grade glioma models.
    Neuro Oncol. 2020 Dec 1. pii: 6015051. doi: 10.1093.
    >> Share

    November 2020
  760. KHASRAW M, Walsh KM, Heimberger AB, Ashley DM, et al
    What is the Burden of Proof for Tumor Mutational Burden in gliomas?
    Neuro Oncol. 2020 Nov 30. pii: 6012765. doi: 10.1093.
    >> Share

  761. LARA-VELAZQUEZ M, Zarco N, Carrano A, Phillipps J, et al
    Alpha 1-antichymotrypsin contributes to stem cell characteristics and enhances tumorigenicity of Glioblastoma.
    Neuro Oncol. 2020 Nov 29. pii: 6010432. doi: 10.1093.
    >> Share

  762. ZHENG ZQ, Chen JT, Zheng MC, Yang LJ, et al
    Nestin +/CD31 + Cells in the Hypoxic Perivascular Niche Regulate Glioblastoma Chemoresistance by Upregulating JAG1 and DLL4.
    Neuro Oncol. 2020 Nov 29. pii: 6010441. doi: 10.1093.
    >> Share

  763. NIU X, Yang Y, Zhou X, Zhang H, et al
    A prognostic nomogram for patients with newly diagnosed adult thalamic glioma in a surgical cohort.
    Neuro Oncol. 2020 Nov 27. pii: 6007003. doi: 10.1093.
    >> Share

  764. KAUFMANN TJ, Smits M, Boxerman J, Huang R, et al
    Response to Letter to Editor.
    Neuro Oncol. 2020;22:1706-1707.
    >> Share

  765. LE RHUN E, Weller M, Le Deley MC
    DEPOSEIN-how meaningful was the benefit from intrathecal chemotherapy?
    Neuro Oncol. 2020;22:1710-1711.
    >> Share

  766. VOGELBAUM MA, Krivosheya D, Borghei-Razavi H, Sanai N, et al
    Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review.
    Neuro Oncol. 2020;22:1568-1579.
    >> Share

  767. OERMANN EK, Germano IM
    In the pursuit of glioma diagnosis - the challenges and opportunities of deep neural network augmented analyses.
    Neuro Oncol. 2020 Nov 12. pii: 5979500. doi: 10.1093.
    >> Share

  768. ALBERT TK, Interlandi M, Sill M, Graf M, et al
    An extracellular vesicle-related gene expression signature identifies high-risk patients in medulloblastoma.
    Neuro Oncol. 2020 Nov 11. pii: 5974128. doi: 10.1093.
    >> Share

  769. MITCHELL K, Troike K, Silver DJ, Lathia JD, et al
    The evolution of the cancer stem cell state in glioblastoma - emerging insights into the next-generation of functional interactions.
    Neuro Oncol. 2020 Nov 11. pii: 5973946. doi: 10.1093.
    >> Share

  770. BERZERO G, Di Stefano AL, Ronchi S, Bielle F, et al
    IDH-wildtype lower grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification.
    Neuro Oncol. 2020 Nov 11. pii: 5973947. doi: 10.1093.
    >> Share

  771. GRAMATZKI D, Felsberg J, Roth P, Kaulich K, et al
    The molecular evolution of glioblastoma treated by gross total resection alone.
    Neuro Oncol. 2020 Nov 11. pii: 5973944. doi: 10.1093.
    >> Share

  772. SAHEBJAM S, Forsyth PA, Tran ND, Arrington JA, et al
    Hypofractionated Stereotactic Re-Irradiation with Pembrolizumab and Bevacizumab in Patients with Recurrent High Grade Gliomas: Results from a Phase 1 Study.
    Neuro Oncol. 2020 Nov 11. pii: 5973945. doi: 10.1093.
    >> Share

  773. YI K, Zhan Q, Wang Q, Tan Y, et al
    PTRF/Cavin1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2.
    Neuro Oncol. 2020 Nov 3. pii: 5952479. doi: 10.1093.
    >> Share

  774. VITANZA NA, Biery MC, Myers C, Ferguson E, et al
    Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naive diffuse midline glioma models.
    Neuro Oncol. 2020 Nov 1. pii: 5948533. doi: 10.1093.
    >> Share

  775. MANJUNATH M, Yan J, Youn Y, Drucker KL, et al
    Functional analysis of low-grade glioma genetic variants predicts key target genes and transcription factors.
    Neuro Oncol. 2020 Nov 1. pii: 5948532. doi: 10.1093.
    >> Share

  776. DEJAEGHER J, Solie L, Hunin Z, Sciot R, et al
    DNA Methylation based glioblastoma subclassification is related to tumoral T cell infiltration and patient survival.
    Neuro Oncol. 2020 Nov 1. pii: 5948531. doi: 10.1093.
    >> Share

  777. KLEIN M, Drijver AJ, van den Bent MJ, Bromberg JC, et al
    Memory in low-grade glioma patients treated with radiotherapy or Temozolomide. A correlative analysis of EORTC study 22033-26033.
    Neuro Oncol. 2020 Nov 1. pii: 5948535. doi: 10.1093.
    >> Share

  778. SIEVERS P, Sill M, Schrimpf D, Stichel D, et al
    A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR.
    Neuro Oncol. 2020 Nov 1. pii: 5948536. doi: 10.1093.
    >> Share

  779. JI SY, Lee J, Lee JH, Lee ST, et al
    Radiological assessment schedule for high-grade glioma patients during the surveillance period using parametric modeling.
    Neuro Oncol. 2020 Nov 1. pii: 5948534. doi: 10.1093.
    >> Share

    October 2020
  780. OSTROM QT, Patil N, Cioffi G, Waite K, et al
    CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017.
    Neuro Oncol. 2020;22.
    >> Share

  781. TENG J, Hejazi S, Hiddingh L, Carvalho L, et al
    Corrigendum to: Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
    Neuro Oncol. 2020 Oct 28. pii: 5942594. doi: 10.1093.
    >> Share

  782. CICONE F, Carideo L, Scaringi C, Romano A, et al
    Long-term metabolic evolution of brain metastases with suspected radiation necrosis following stereotactic radiosurgery: longitudinal assessment by F-DOPA PET.
    Neuro Oncol. 2020 Oct 23. pii: 5936979. doi: 10.1093.
    >> Share

  783. MYNAREK M, Rutkowski S
    Young children with medulloblastoma: Important open questions and the high-risk dilemma.
    Neuro Oncol. 2020 Oct 23. pii: 5936023. doi: 10.1093.
    >> Share

  784. GONDI V, Mehta MP
    Radiotherapy Innovations to Optimize Brain Metastases Control.
    Neuro Oncol. 2020 Oct 22. pii: 5934824. doi: 10.1093.
    >> Share

  785. BROSSIER NM, Thondapu S, Cobb OM, Dahiya S, et al
    Temporal, spatial, and genetic constraints contribute to the patterning and penetrance of murine Neurofibromatosis-1 optic glioma.
    Neuro Oncol. 2020 Oct 20. pii: 5932401. doi: 10.1093.
    >> Share

  786. CHO SJ, Sunwoo L, Baik SH, Bae YJ, et al
    Brain Metastasis Detection using Machine Learning: A Systematic Review and Meta-analysis.
    Neuro Oncol. 2020 Oct 19. pii: 5930826. doi: 10.1093.
    >> Share

  787. GROSSMAN SA
    The Duration of Adjuvant Temozolomide in Patients with Glioblastoma and the Law of Diminishing Returns.
    Neuro Oncol. 2020 Oct 19. pii: 5930402. doi: 10.1093.
    >> Share

  788. SKINNER KR, Nabors LB, Miller CR
    Mapping uncharted territory: a gene expression signature for precision glioblastoma therapeutics.
    Neuro Oncol. 2020 Oct 19. pii: 5930390. doi: 10.1093.
    >> Share

  789. ZHUANG H, Wang Y, Cheng C, Shi S, et al
    The efficacy of anlotinib instead of glucocorticoids for edema induced by brain metastases in NSCLC patients with anti-PD1/PDL-1 immunotherapy.
    Neuro Oncol. 2020 Oct 19. pii: 5930379. doi: 10.1093.
    >> Share

  790. YOUNGBLOOD MW, Miyagishima DF, Jin L, Gupte T, et al
    Associations of Meningioma Molecular Subgroup and Tumor Recurrence.
    Neuro Oncol. 2020 Oct 17. pii: 5928913. doi: 10.1093.
    >> Share

  791. LAMBA N, Kearney RB, Catalano PJ, Hassett MJ, et al
    Population-based estimates of survival among elderly patients with brain metastases.
    Neuro Oncol. 2020 Oct 17. pii: 5929216. doi: 10.1093.
    >> Share

  792. BEIG N, Singh S, Bera K, Prasanna P, et al
    Sexually dimorphic radiogenomic models identify distinct imaging and biological pathways that are prognostic of overall survival in Glioblastoma.
    Neuro Oncol. 2020 Oct 17. pii: 5929182. doi: 10.1093.
    >> Share

  793. BINDRA RS
    Penetrating the Brain Tumor Space with DNA Damage Response Inhibitors.
    Neuro Oncol. 2020 Oct 16. pii: 5924496. doi: 10.1093.
    >> Share

  794. OPITZ CA, Turcan S
    From anti-aging drugs to cancer therapy: Is there a potential for sirtuin activators in gliomas?
    Neuro Oncol. 2020 Oct 16. pii: 5924499. doi: 10.1093.
    >> Share

  795. ALNAHHAS I, Rayi A, Ong S, Giglio P, et al
    Management of gliomas in patients with Lynch Syndrome.
    Neuro Oncol. 2020 Oct 16. pii: 5924485. doi: 10.1093.
    >> Share

  796. CHAMBERLAIN MC
    Leptomeningeal metastases: how best to assess response.
    Neuro Oncol. 2020;22:1417-1418.
    >> Share

  797. ROSSI M, Gay L, Ambrogi F, Nibali MC, et al
    Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas.
    Neuro Oncol. 2020 Oct 13. pii: 5922564. doi: 10.1093.
    >> Share

    September 2020
  798. DAS S
    The ethics of neuro-oncology in the era of COVID-19: lessons to be learned.
    Neuro Oncol. 2020;22:1399.
    >> Share

  799. XU W, Hu X, Zhang J
    Letter regarding article "Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion".
    Neuro Oncol. 2020;22:1400-1401.
    >> Share

  800. KOTECHA R, Yomo S, Suh JH
    Response to letter regarding "Stereotactic radiosurgery for nonfunctioning pituitary adenomas: meta-analysis and International Society of Stereotactic Radiosurgery (ISRS) practice opinion".
    Neuro Oncol. 2020;22:1402-1403.
    >> Share

  801. TSANG DS, Kim L, Liu ZA, Janzen L, et al
    Intellectual changes after radiation for children with brain tumors: which brain structures are most important?
    Neuro Oncol. 2020 Sep 16. pii: 5906521. doi: 10.1093.
    >> Share

    August 2020
  802. GUERREIRO STUCKLIN AS, Mueller S
    Opportunities for the treatment of NF1-associated low-grade gliomas: how to decide on the best treatment options for patients?
    Neuro Oncol. 2020 Aug 25. pii: 5896906. doi: 10.1093.
    >> Share

  803. BOHM AK, DePetro J, Binding CE, Gerber A, et al
    In vitro modeling of glioblastoma initiation using PDGF-AA and p53-null neural progenitors.
    Neuro Oncol. 2020;22:1150-1161.
    >> Share

  804. SHI C, Ye Z, Han J, Ye X, et al
    BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma.
    Neuro Oncol. 2020;22:1114-1125.
    >> Share

  805. WICK A, Kessler T, Platten M, Meisner C, et al
    Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma.
    Neuro Oncol. 2020;22:1162-1172.
    >> Share

    July 2020
  806. KARREMAN MA, Winkler F
    Targeting an adhesion molecule to prevent brain colonization of lung cancer.
    Neuro Oncol. 2020;22:899-900.
    >> Share

  807. GEURTS M, van den Bent MJ
    Fast-growing oligodendrogliomas are aggressive tumors-the real life biomarker?
    Neuro Oncol. 2020;22:907-908.
    >> Share

  808. COLO F, Larrouquere L, Rivoirard R, Loiseau H, et al
    Bevacizumab in progressive disseminated atypical choroid plexus papilloma in adults.
    Neuro Oncol. 2020;22:1046-1047.
    >> Share

  809. JAIN R, Johnson DR, Patel SH, Castillo M, et al
    "Real world" use of a highly reliable imaging sign: "T2-FLAIR mismatch" for identification of IDH mutant astrocytomas.
    Neuro Oncol. 2020;22:936-943.
    >> Share

  810. ROUX A, Tauziede-Espariat A, Zanello M, Peeters S, et al
    Imaging growth as a predictor of grade of malignancy and aggressiveness of IDH-mutant and 1p/19q-codeleted oligodendrogliomas in adults.
    Neuro Oncol. 2020;22:993-1005.
    >> Share

    June 2020
  811. BENNETT J, Bouffet E
    Neuro-oncology in adolescents and young adults-an unmet need.
    Neuro Oncol. 2020;22:752-753.
    >> Share

  812. HU LS, Swanson KR
    Roadmap for the clinical integration of radiomics in neuro-oncology.
    Neuro Oncol. 2020;22:743-745.
    >> Share

    March 2020
  813. KOTECHA R, Sahgal A, Rubens M, De Salles A, et al
    Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion.
    Neuro Oncol. 2020;22:318-332.
    >> Share

  814. LASOCKI A, Khoo C, Lau PKH, Kok DL, et al
    High-resolution MRI demonstrates that more than 90% of small intracranial melanoma metastases develop in close relationship to the leptomeninges.
    Neuro Oncol. 2020;22:423-432.
    >> Share

    February 2020
  815. OSTROM QT, Kruchko C, Barnholtz-Sloan JS
    Pilocytic astrocytomas: where do they belong in cancer reporting?
    Neuro Oncol. 2020;22:298-300.
    >> Share

    January 2020
  816. TEW BY, Legendre C, Schroeder MA, Triche T, et al
    Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones.
    Neuro Oncol. 2020;22:70-83.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016